Document:

EX-10.12

 Exhibit 10.12 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if
publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. 

Purchase Agreement Between CVS Pharmacy, Inc. 

And 
 LumiraDx, Inc

  

	1.	 Overview and Background of Agreement 

This Purchase Agreement (this “Agreement”) is effective 14 August 2020 (“Effective Date”) by and between LumiraDx
Inc, a Delaware corporation, with offices located at 221 Crescent Street, Waltham, MA 02453 (“Vendor or LumiraDx”) and CVS Pharmacy, Inc., a Rhode Island corporation, on its own behalf and on behalf of its subsidiaries and
affiliates, including without limitation MinuteClinic, L.L.C. on behalf of itself, its subsidiaries and its managed entities, with offices located at One CVS Drive, Woonsocket, RI 02895 (hereinafter individually and collectively called
“CVS”). 
 Vendor is the developer of the LumiraDx Platform, a portable point of care test system (the “LumiraDx
Instrument”). Vendor is in the process of developing a COVID-19 antigen assay test strip as well as a COVID-19 antibody assay test strip (collectively, the
“COVID-19 Test Strips”) which can run on Vendor’s LumiraDx Instrument. 

Vendor is seeking Emergency Use Authorization from the Food and Drug Administration (“EUA FDA Approval”) for the LumiraDx
Instrument and COVID-19 Test Strips. Vendor acknowledges that additional FDA approvals may need to be obtained in the future, in addition to the EUA FDA Approval(s) (collectively the “FDA
Approvals”). 
 The obligations set forth in this Agreement are subject to Vendor obtaining and maintaining the appropriate FDA
Approvals now and in the future for the LumiraDx Instrument and COVID-19 Test Strips as well as the ancillary equipment, including collection supplies (“Ancillary Equipment”) necessary to
administer the tests (collectively the “Products”) that expressly authorizes use of the LumiraDx Instrument and COVID-19 Tests strips in patient care settings outside of the clinical
laboratory environment. If Vendor fails to obtain and/or maintain FDA Approvals required for Vendor to make the Products available to CVS and for CVS to be able to use, sell and distribute the Products in compliance with all applicable laws
(including but not limited to laws, statutes, codes, ordinances, rules, regulations, declarations, decrees, directives, recognized international and local industry quality standards, legislative enactments and court (or other governmental,
administrative or regulatory) orders, including the U.S. Federal Food, Drug and Cosmetic Act (21 U.S.C. § 321 et seq.) and health authority requirements) (“Applicable Laws”) in effect as of July 31, 2020, Vendor will be
entitled to terminate this Agreement as set forth in Section 5.2. 

	2.	 Product Provided 

 

	 	2.1	 Geographic Scope and Shipping 

Vendor agrees to make the Products available in the United States, including its territories, provinces and possessions (collectively the
“United States”), to CVS for purchase to the designated CVS regional distribution centers or through an approved distributor designated by CVS, such designated distributor may be changed in CVS’s sole discretion provided the
total costs related to utilization of such new distributor shall not increase more than [***], in which case Vendor approval shall be required, which shall not be unreasonably withheld. Costs related to utilization of a distributor will be shared
equally between the Parties subject to the following allocation: CVS [***] and Vendor [***]. If a distributor is not utilized, Vendor will ship the Products to designated CVS regional distribution centers FOB Origin utilizing CVS’s Routing
Guide & Vendor Compliance Instructions, available at www.cvs.suppliers.com, as may be updated by CVS from time to time, subject to acceptance of any material changes by Vendor. 

 

	 	2.2	 Product Allocation and Purchase 

Vendor agrees to sell the Products to CVS, and CVS agrees to purchase the Products from Vendor, subject to the terms and conditions in this
Agreement. 
 LumiraDx commits to make a minimum monthly quantity of the Products available for CVS to purchase as set forth in Exhibit
A, as it may be amended from time to time by mutual agreement of the parties. CVS is not obligated to make any minimum purchases under this Agreement.  

An initial purchase order for Products shall be placed within [***] of receipt by Vendor of the EUA FDA Approval for the SARS-COV antigen test. CVS warrants that it will not utilize any Products purchased prior to Vendor obtaining the necessary EUA FDA Approval. For purposes of this Agreement, “Business Day” means any day
that the New York Stock Exchange is open for trading. 
 Thereafter, [***] prior to the end of each month, CVS shall place a confirmatory
purchase order for the following month identifying the number of LumiraDx Instruments, COVID-19 Test Strips and/or Ancillary Equipment it desires to purchase. If CVS shall fail to place such confirmatory
purchase order, or such order for the LumiraDx Instruments or COVID-19 Test Strips is for quantities less than the monthly allocation listed on Exhibit A, CVS shall not be entitled to such monthly allocation
explicitly tied to such Product type for that month and LumiraDx shall have no obligation to ensure that any shortfall on such purchase order shall roll over and be added to the allocation for the subsequent month. 

Should CVS fail to place any confirmatory purchase order for a consecutive [***] period for the LumiraDx Instruments or the COVID-19 Test Strips, then Vendor and CVS shall adjust the allocation for such Product as set forth on Exhibit A. For the avoidance of doubt and by way of example, CVS’s failure to place a purchase order for
the LumiraDx Instruments shall only extinguish CVS’s entitlement to the corresponding LumiraDx Instruments and shall not modify, remove, nor diminish CVS’s 

 
entitlement to the allocated COVID-19 Test Strips, or vice-versa, as long as such purchase order was placed. CVS shall not be obligated to order or accept
any LumiraDx Instrument where the COVID-19 Test Strip allocation is less than [***] COVID-19 Test Strips per month per LumiraDx Instrument. Vendor may, subject to
availability, make available additional quantities of Products for CVS to purchase, but unless such confirmatory purchase orders are placed timely, Vendor shall not be required to hold such additional monthly quantities for purchase by CVS. 

If Vendor fails to obtain the appropriate and required FDA Approval(s) prior to August 31, 2020, CVS, or its designated distributor on
its behalf, as applicable, retains the right to return any purchased unused Products to Vendor and receive a full refund for any amounts paid to Vendor for such unused Products. 

If at any point during the Term, Vendor fails to maintain the appropriate and required FDA Approval(s), CVS, or its designated distributor on
its behalf, as applicable, retains the right to return any purchased unused Products to Vendor and receive a full refund for any amounts paid to Vendor for such unused Products. If at any point during the Term, any unused COVID-19 Test Strips are delivered to CVS, or its designated distributor on its behalf, with an expiration date of [***] or less, CVS, or its designated distributor on its behalf, as applicable, retains the right to
obtain replacement COVID-19 Test Strips for such COVID-19 Test Strips. 

Each Product’s date of manufacture and expiration, if any, shall be clearly marked at the unit level or smallest quantity grouping for
each Product type. 
  

	3.	 Management Reporting and Communications 

 

	 	3.1	 Vendor Reporting 

Vendor agrees to provide CVS with reports on a monthly basis or as required by CVS, inclusive of but not limited to explanations for any
significant variances or scheduling delays. Vendor may also be required to report other key metrics as defined by additional exhibits to CVS on a monthly basis. Such financial and operational communications shall be provided to CVS in electronic
copies. 
  

	 	3.2	 Communications from CVS to Vendor 

CVS agrees to submit a purchase order to Vendor that specifies the quantity, identification, destination address, and delivery date of the
Products to be ordered. 
 CVS will attempt to provide Vendor with the necessary purchase order numbers and confirmations as far in advance
of the requested shipment arrival date as possible. All orders will be placed by CVS or its designated distributor to the designated associate at Vendor as agreed upon by CVS. 

 

	4.	 Financial Arrangements & Pricing 

 

	 	4.1	 Nature of Financial Arrangements 

Subject to Section 2.1, CVS agrees to pay Vendor at the rates set forth in Exhibit B for the corresponding types of Product and/or
Ancillary Equipment. 

	 	4.2	 Preferred Vendor Status COVID-19 Test Strips: CVS is a preferred
Vendor customer for Products to be used in the United States. Vendor agrees that on a quarterly basis during the Term of this Agreement, it will provide an attestation that, upon information and belief and to the best of its knowledge, as a
preferred Vendor customer, CVS is receiving the best price and is not paying more than any other Vendor customer who is using the COVID-19 Test strips to perform point of care testing in the United States (an
“End User”). End Users do not include purchasers who are a United States Federal or state government agency. If Vendor becomes aware that another End User is receiving better pricing than CVS on purchases of the COVID-19 Test Strips, Vendor will automatically adjust the price of the COVID-19 Test Strips purchased under this Agreement to extend the same pricing to CVS for all future
purchases. Similarly, if CVS provides good faith notice to Vendor that it believes another End User is receiving better pricing, Vendor shall undertake efforts to verify and, if verified, shall extend such pricing to CVS for future purchases. [***]
CVS shall have the right to audit Vendor’s compliance with these obligations pursuant to Section 9. 

  

	 	4.3	 Price Adjustments 

Unless the parties mutually agree in writing to modify Exhibit B, Product prices will be fixed at the rates shown in Exhibit B
so long as this Agreement is in effect except if modified as set forth above in Section 4.2 to provide CVS with the price(s) offered to another Vendor customer. 
  

	 	4.4	 Billing/Monthly Payment Procedures 

Vendor invoices will contain the quantity of each order of Product delivered and the shipping date thereof, applicable unit prices, and any
other information that CVS may from time to time reasonably request hereunder. 
 Products purchased during the first two months from the
date of first purchase order shall be paid pursuant to Vendor’s invoices within [***] from the date of CVS’s receipt of such invoice, other than amounts disputed in good faith. For all subsequent orders and purchases, CVS will pay Vendor
all other amounts due for Products pursuant to Vendor’s invoices within [***] from the date of CVS’s receipt of LumiraDx’s invoice, other than amounts disputed in good faith. In case of
non-payment with regards to Products where there is not a good faith dispute, Vendor shall be entitled to suspend future shipments of Products until payment is made, following a Notice of non-payment which remains uncured. 
 Payment of invoices will not constitute acceptance of Product and
will in no way be considered a waiver of any right of CVS with respect to its remedies hereunder for non-conforming Product or deliveries or other performance or nonperformance by Vendor of its obligations
hereunder or for failure of Vendor to comply with the provisions of this Agreement. Notwithstanding anything in this Agreement to the contrary, CVS’s obligation to pay Vendor shall be conditioned on the prior receipt from Vendor of a complete
and accurate Form W-9 or similar form that is satisfactory to CVS. 

	 	4.5	 Taxes 

The parties’ respective responsibilities for taxes arising under or in connection with this Agreement are as follows: 

Vendor shall separately identify any Transaction Taxes on its invoices (written or electronic) to CVS. CVS agrees to pay any Transaction Taxes
separately identified by Vendor on its invoices, unless CVS provides Vendor with a valid and applicable exemption, direct pay or resale certificate. Any failure by Vendor to charge Transaction Taxes on its invoices shall not result in a liability to
CVS at a later date. For purposes of this Agreement, “Transaction Taxes” mean any sales, use, transaction privilege or any other similar tax, fee or surcharge statutorily imposed by a taxing authority on the sale of products and/or
services by Vendor to CVS pursuant to the terms of this Agreement. 
 Each Vendor invoice shall provide sufficient detail, including without
limitation, location of product delivery or service performance, to support Vendor’s tax treatment of any transaction reflected on an invoice. 

Vendor shall timely file any applicable returns or filings and shall timely remit all Transaction Taxes collected from CVS to the appropriate
taxing authority as required by law. Vendor shall maintain its records, including without limitation, copies of invoices, related documentation and tax returns/filings for a period of not less than [***]. 

Upon written request by CVS, Vendor agrees to provide CVS a list of states, localities, municipalities or other taxing jurisdictions and
corresponding registration numbers for each jurisdiction where Vendor is qualified and registered to do business and collect any Transaction Taxes. If Vendor does not respond in writing to CVS’s request within [***], then CVS shall have the
right, in its sole discretion, to remit the appropriate tax directly to the taxing jurisdiction or withhold payment until the time that such information is provided by Vendor. 

CVS and Vendor agree to cooperate in the audit and minimization of Transaction Taxes in connection with this Agreement. Vendor shall make
available to CVS on a timely basis all information, records, invoices, returns and/or other documentation related to the collection or payment of any Transaction Taxes under this Agreement. 

Vendor agrees that any overpayment of Transaction Taxes by CVS shall be credited or refunded to CVS in a timely manner. 

Vendor shall assume any and all liability for its noncompliance with the terms of this Section, including any interest and penalty assessments
to the extent caused by Vendor’s actions, errors, omissions or inactions. 
 Notwithstanding any provision herein to the contrary, each
party shall be responsible for any income, gross receipts, franchise, corporate excise, payroll, payroll withholding, unemployment or similar types of taxes based on its own income, its own business and for its own employees. 

The provisions of this Section shall survive expiration or termination of this Agreement. 

	5.	 Term and Termination 

 

	 	5.1	 Term 

This Agreement will take effect as of the Effective Date and will continue through December 31, 2021. This Agreement may be renewed or
extended for an additional period of time only by written agreement of the parties. 
  

	 	5.2	 Termination 

For Convenience. CVS may terminate this Agreement without cause upon [***] prior written Notice to the other party. Such written Notice shall
be provided to the parties set forth in Section 12.2 below. 
 For Cause: 

 

	 	(i)	 If either party materially breaches a provision of this Agreement, the other party may give the breaching party
written Notice of such breach. If the breach is not remedied within thirty (30) days thereafter, the party giving Notice shall have the right to terminate this Agreement without further Notice. The rights of termination referred to in this
Section are not intended to be exclusive and are in addition to any other rights and remedies available to either party at law or in equity. 

  

	 	(ii)	 Either party hereto shall have the right to immediately terminate this Agreement and any purchase order for
Products upon written Notice to the other in the event of the other party’s insolvency or receivership; if the other party becomes the debtor in a voluntary or involuntary bankruptcy case; in the event that any part of the other’s property
is or becomes subject to any levy, seizure, assignment or sale from or by a creditor or receiver. 

  

	 	(iii)	 CVS shall have the right to immediately terminate this Agreement and any purchase order for Products upon
written Notice if Vendor fails to obtain and/or maintain any required FDA Approval(s). 

  

	 	5.3	 Effect of Termination 

Upon the effective termination date, all undisputed outstanding amounts shall become due and payable. In the event of termination for any
reason other than Vendor’s breach, Vendor shall provide all ordered Products to CVS within thirty (30) days of the effective termination date. If CVS terminates for cause as set forth above in Section 5.2, CVS may return any unused
Products to Vendor and receive a full refund of any amounts paid. 
 Sections 2, 5, 6, 7, 8, 9, 11, 12.2, and 12.4 shall survive the
expiration or termination of this Agreement. 
  

	6.	 Confidentiality of Data Provided / Non-Publicity

  

	 	6.1	 Confidentiality of Data Provided 

CVS and Vendor will maintain the confidentiality of information shared between the parties in connection with this Agreement in accordance
with the Mutual Non-Disclosure Agreement (“NDA”) between the parties with an effective date of March 23, 2018. 

	 	6.2	 [***] 

  

	 	6.3	 Non-Publicity 

Vendor agrees that neither it nor any of its employees, agents, or subcontractors shall use CVS’s name or any photo or visual or audio
facsimiles of CVS’ facilities or employees for any purpose. Each party agrees that it shall not, and its employees, agents and subcontractors shall not, reveal the nature of the goods and services provided to the other party pursuant hereto, or
any details regarding the goods and services provided pursuant hereto, to any third party for any purpose, unless prior written consent of such other party has been obtained. Vendor shall not use, disseminate, disclose, or publish any work product
or any other materials related to such goods and services in whole or part without prior written consent of CVS. 
  

	7.	 Independent Contractor 

 

	 	7.1	 Independent Contractor 

Vendor shall perform all obligations hereunder as an independent contractor and not as any agent or employee of CVS. Vendor shall make no
representations that it has the authority to bind CVS to any obligation to any third party. 
  

	 	7.2	 [***] 

  

	8.	 Indemnification by Vendor and Insurance 

 

	 	8.1	 Indemnification 

Vendor agrees (i) to indemnify and hold harmless CVS from and against any claims, liabilities and damages to the extent same are due to
Vendor’s negligence, willful misconduct, or breach of this Agreement or Vendor’s failure to comply with or abide by any Applicable Law (other than by reason of an act or omission of CVS), and (ii) to defend promptly and diligently, at
Vendor’s sole expense, with reasonable and documented attorneys’ fees reasonably acceptable to CVS, any claim, action or proceeding brought against CVS or CVS and Vendor jointly or severally, arising out of or connected with any of the
foregoing, and to indemnify and hold CVS harmless from any judgment, loss, or settlement on account thereof. Vendor’s duty to defend CVS under this Section shall apply to any complaint or claim that makes allegations that, if proved, place the
alleged breach of duty, whether in tort or contract, potentially within the purview of the duties, responsibilities and obligations undertaken by Vendor pursuant to this Agreement. 

Vendor agrees to indemnify and defend CVS and any employee or agent thereof against all liability to third parties (other than liability
arising from the actions of CVS or its employees or agents) arising from the violation of any third party’s trade secrets, proprietary information, trademark, copyright, or patent rights in connection with the Products provided hereunder,
regardless of whether CVS provided the specifications for the Products or contributed to the design of the Products to any extent or in any capacity. Vendor shall conduct the defense in any such third party action arising as described herein at its
sole expense and CVS promises to fully cooperate with such defense. 
 The provisions of this Section shall survive the expiration or
termination of this Agreement. 

	 	8.2	 Insurance 

During the term of this contract, Vendor shall, at its expense, carry and maintain: 

 

	 	a)	 Workers Compensation and Employers Liability Insurance meeting minimum statutory requirements,

  

	 	b)	 Commercial Umbrella and/or Employers Liability Limits of no less than [***] each accident for bodily injury and
[***] each employee for bodily injury by disease, 

  

	 	c)	 Commercial General Liability (CGL) and/or Umbrella Liability insurance written on ISO Occurrence form CG 00 01
12 07 or equivalent, with a limit of not less than [***] each occurrence, [***] General Aggregate and [***] Products Completed Operations Aggregate, and 

  

	 	d)	 Automobile Liability and/or Umbrella Liability insurance with limits of not less than [***] each accident.

 The policies shall be underwritten by an insurance company that carries an A-
or better rating from A.M. Best. Each policy (except for Worker’s Compensation) shall provide that: 
  

	 	1.	 CVS Health Corporation and its subsidiaries and affiliates shall be named as additional insureds,

  

	 	2.	 not less than thirty (30) days’ prior written notice shall be given to CVS Health Corporation in the
event of any alteration or terms of such policy or of the cancellation or non-renewal thereof, 

	 	3.	 such insurance (except for Worker’s Compensation) will be primary insurance with respect to CVS Health
Corporation and its subsidiaries and affiliates, and 

  

	 	4.	 Vendor will provide a Waiver of Subrogation against CVS Health Corporation and its agents, officers, directors
and employees for recovery of damages against these policies. 

 Vendor shall furnish CVS Health Corporation with a
Certificate of Insurance evidencing coverage, and a Certificate of Insurance as evidence of renewal at least thirty (30) days prior to expiration of each policy. The amount of such required insurance coverage under this Section shall not limit
Vendor’s obligations under this Agreement. 
  

	9.	 Right to Audit 

CVS, in its sole discretion, shall have the right, but not the obligation, to (i) audit or hire a third party auditor or (ii) allow
(1) state or federal government regulators such as Center for Medicare and Medicaid Services, (2) CVS Pharmacy Benefit Management clients, or (3) accreditation agencies such as URAC, to audit any and all business and operations practices
and procedures of Vendor as they pertain to this Agreement, including, but not limited to, billing practices and procedures. CVS will also have the right to verify / audit the commitments set forth in Section 4.2 are being met via use of an
outside audit company. CVS or its designated agent shall perform any such audits at mutually agreed to times during regular business hours and not more than [***] per year, unless where requested by an external agency. CVS shall provide prior
reasonable notice of an audit to Vendor. Following such audit, CVS may provide a written report of its findings to Vendor, including a timetable for correction of any issues or problems discovered by the auditors. In the event Vendor fails to
correct such issues or problems in a timely manner satisfactory to CVS, this Agreement may be terminated 

 
by CVS for cause in accordance with Section 5.2. Any audit shall be subject to Vendor’s security and confidentiality procedures. Vendor shall be solely responsible for paying the
internal costs and expenses it incurs in connection with an audit conducted under this Section 9 along with any costs and/or expenses associated with any remediation efforts. 

All costs and expenses incurred by CVS for such an audit will be paid by CVS, unless the inspection discloses errors or omissions more than
[***] percent of the invoiced amount in Vendor’s favor in which case the costs and expenses will be paid by Vendor. In the event that an audit discloses any overcharges, the prices will be adjusted to be in accordance with the terms of this
Agreement and the total amount so determined to be overcharged, at CVS’ option, will promptly be credited to the account of CVS or paid to CVS, within thirty (30) days of such finding. 

 

	10.	 Business Continuity 

Vendor shall have a business continuity plan in place to [***]. Vendor shall provide a copy of its business continuity plan to CVS Health
upon written request. Annually, Vendor shall assess and update its business continuity plan in light of current business and technology risks and shall attest to CVS that it has assessed and updated its business continuity plan and capabilities
accordingly. 
  

	11.	 Confirmations, Warranties and Liabilities 

 

	 	11.1	 Vendor shall use commercially reasonable efforts to make the LumiraDx Instrument and COVID-19 Test Strips available for purchase by CVS as soon as the EUA FDA Approval for use in patient care settings outside a clinical laboratory is obtained. If requested by CVS, Vendor shall provide to CVS copies
of the information submitted to the FDA in connection with their application for EUA FDA Approval, any subsequent FDA Approval applications and all correspondence with the FDA. 

 

	 	11.2	 Vendor Warranty: With regards to the LumiraDx Instrument for a period of [***] from date of purchase and
with regards to the COVID-19 Test Strips as per their referenced shelf life, LumiraDx warrants, to CVS, as the original purchaser whether purchased directly or through its designated distributor, that each
Product shall be (i) of good quality and free of material defects, (ii) function in accordance with the material specifications referenced in the Product Insert or Instrument User Manual, and (iii) approved by the proper governmental
agencies required for the sale of products for their intended use (the “limited warranty”). If any Product fails to meet the requirements of the applicable limited warranty, then, LumiraDx shall either repair or replace, at LumiraDx’s
discretion, the LumiraDx Instrument or COVID-19 Test Strips, as applicable. Except for the limited warranty stated in this section, LumiraDx disclaims any and all warranties, express or implied, including but
not limited to, any warranty of merchantability and fitness for a particular purpose regarding the Product. The limited warranty above shall not apply if the customer has subjected the LumiraDx Instrument or
COVID-19 Test Strips to physical abuse, misuse, abnormal use, use inconsistent with the LumiraDx Instrument User Manual or Product Insert, fraud, tampering, unusual physical stress, negligence or accidents.
Unused strips must be stored according to the required storage conditions as printed in this product insert and they can be used only up to the expiry date printed on the Test Strip pouch and Test Strip box. Any warranty claims by CVS pursuant to
the limited warranty shall be made in writing within the 

	 	
applicable limited warranty period. In the event a Product does not conform to the Product Warranty in any respect, Vendor shall, either: (i) accept return of the defective Product and
repair or have repaired the defective Product; or (ii) accept return of the defective Product and provide a replacement Product to CVS. Vendor shall bear the direct costs and expenses of repair and replacement, and Vendor will take all
necessary steps to provide repaired or replacement Products to CVS or its designated distributor. 

  

	 	11.3	 LIMITATION OF LIABILITY. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR TO ANY OTHER
PERSON OR ENTITY UNDER ANY EQUITY, COMMON LAW, TORT, CONTRACT, ESTOPPEL, NEGLIGENCE, STRICT LIABILITY, OR OTHER THEORY, FOR ANY SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE, CONSEQUENTIAL OR CONTINGENT DAMAGES, OR ANY DAMAGES RESULTING FROM LOSS OF SALE,
BUSINESS, PROFITS, DATA, OPPORTUNITY OR GOODWILL, EVEN IF THE REMEDIES PROVIDED FOR IN THIS AGREEMENT FAIL OF THEIR ESSENTIAL PURPOSE, AND EVEN IF THE OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. 

The exclusions and limitations of this Section 11.3 do not apply (a) to the extent prohibited by applicable law, (b) to damages
arising in connection with the Vendor’s indemnity obligations set forth in Section 8.1, (c) to breach of either party’s confidentiality obligations, or (d) to damages arising out of either party’s fraud, gross negligence or
willful misconduct. 
  

	12.	 Other Provisions 

 

	 	12.1	 Assignment 

Neither party shall assign, subcontract, or otherwise transfer its rights or obligations under this Agreement except with the prior written
consent of the other, said consent not to be unreasonably withheld; provided, however, either party shall have the right to assign this Agreement to any present or future affiliates, subsidiary, or parent corporation of such party, or pursuant to a
corporate plan of merger, reorganization, or consolidation without securing the consent of Vendor and may grant to any such assignee the same rights and privileges such other party enjoys under this Agreement. Any attempted assignment not assented
to in the manner as prescribed herein, except an assignment confined solely to monies due or to become due, shall be void. 
  

	 	12.2	 Notices 

Any Notice (“Notice”) by either party to the other shall be made by registered or certified mail or by overnight courier
service, provided that a receipt is required, and mailed to the addresses noted below, which may be changed by either party by written Notice to the other party. 

To CVS: 
 CVS Pharmacy, Inc.

 One CVS Drive 
 Woonsocket,
RI 02895 
 Attention: [***] 

 Copy To: [***] 

To Vendor: 
 LumiraDx Inc 

221 Crescent Street 
 Waltham,
MA 02453 
 Attention: CFO 
  

	 	12.3	 Severability 

If any provision of this Agreement or the application thereof to any persons or circumstances shall to any extent be invalid or unenforceable,
the remainder of this Agreement or the application of such provision to persons or circumstances other than those to which it is held invalid or unenforceable shall not be affected thereby, and each provision of this Agreement shall be valid and
enforceable to the fullest extent permitted by law. 
  

	 	12.4	 Governing Law 

This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to the conflict of
law provisions thereof. 
  

	 	12.5	 Compliance with Non-Discrimination and Authorization to Work
Requirements 

 CVS and Vendor shall abide by the requirements of 41 CFR §§ 60-1.4(a), 60-300.5(a) and 60-741.5(a). These regulations prohibit discrimination against qualified individuals based on their status
as protected veterans or individuals with disabilities, and prohibit discrimination against all individuals based on their race, color, religion, sex, or national origin. Moreover, these regulations require that covered prime contractors and
subcontractors take affirmative action to employ and advance in employment individuals without regard to race, color, religion, sex, national origin, protected veteran status or disability. 

 

	 	12.5.1	 Vendor agrees to post in conspicuous places, available for employees and applicants for employment, notices to
be provided by the contracting officer setting forth the provisions of the nondiscrimination clause. 

  

	 	12.5.2	 The parties incorporate into this Agreement, as applicable, the obligations regarding the notice of employee
rights under federal labor laws found at 29 CFR Part 471, Appendix A to Subpart A, and Vendor will likewise incorporate those obligations into all applicable subcontracts as required by 29 CFR Part 471. 

 

	 	12.5.3	 Where Vendor will be providing services, deliverables or other items to CVS pursuant to this Agreement in
connection with federal contracts or subcontracts of $100,000 or more, then CVS and Vendor must file VETS-100A reports by September 30 of each year, or any applicable extension deadline that VETS announces. 41 CFR Part 61-300. 

	 	12.5.4	 Vendor agrees that it will comply with all laws, regulations, and applicable executive orders governing
verification of an employee’s authorization to work in the United States and agrees that it will allow only employees who are authorized to work in the United States to perform work pursuant to this Agreement. 

 

	 	12.5.5	 Vendor certifies that Vendor, its subcontractors and the employees of each are authorized to work in the United
States pursuant to the Immigration Reform and Control Act of 1986 and that such authorization has been verified through Vendor’s or subcontractor’s use of the Department of Homeland Security’s
E-Verify Program, or industry standard equivalent. 

  

	 	12.6	 Debarment and Exclusion 

Each party represents and warrants that neither it, nor any of its employees or agents working on its behalf and providing items and services
pursuant to this Agreement: (i) is currently an Ineligible Person; (ii) has been charged with a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a) or § 1320a-7(b)(l)-(3); or (iii) has been proposed for exclusion, debarment, suspension, or other ineligibility from any Federal health care program or Federal procurement or
non-procurement program. Each party further represents and warrants that if, during the term of this Agreement, it or, with respect to any of its employees or agents working on its behalf and providing items
and services pursuant to this Agreement, it has actual notice that such employee or agent: (i) becomes an Ineligible Person, (ii) is charged with a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a) or § 1320a-7(b)(l)-(3), or (iii) is proposed for exclusion, debarment, suspension, or other ineligibility from any Federal health care program or Federal
procurement or non-procurement program, that party will immediately notify the other party, and such other party will have the right to immediately terminate this Agreement. Vendor agrees to cooperate with any
requests for information by CVS in order to screen Vendor’s employees who are providing items and services pursuant to this Agreement to determine if such employees are Ineligible Persons. Each party agrees to indemnify, defend and hold
harmless, the other party, its officers, directors, shareholders, employees, agents, representatives, affiliates, and assigns (the “Indemnitees”) from any and all liabilities, losses, claims, damages, obligations, costs, and
expenses (including, without limitation, penalties, fines, sanctions, any legal and accounting fees, and expenses, any costs of litigation, investigation, and settlement) that the Indemnitees may incur or suffer as a result of, arising out of, or in
any way connected with (i) such party’s negligence or willful act or omission of any of its obligations under this Section, or (ii) breach by such party of any of its representations and warranties contained in this Section.
“Ineligible Person” means an individual or entity who: (i) is currently excluded, debarred, suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or non-procurement programs; or (ii) has been convicted of a criminal offense that falls within the ambit of 42 U.S.C. § 1320a-7(a), but has not yet been excluded,
debarred, suspended, or otherwise declared ineligible. 
  

	 	12.7	 Entire Agreement 

This Agreement (including all Exhibits) constitutes the entire understanding and Agreement of the parties and supersedes all prior written or
oral agreements with respect to the subject matter in the 

 
Agreement. This Agreement may not be modified or amended unless in writing signed by the parties hereto. Waiver of any provision of the Agreement by a party at any time shall not constitute a
waiver of any other provision of the Agreement, or waiver of the same provision at any other time. 
  

	 	12.8	 Exhibits 

The following Exhibits are incorporated herein by this reference: 

Exhibit A: Product Availability 

Exhibit B: Product Pricing 

Exhibit C: LumiraDx Instrument End User License Agreement 

In the event of any conflict between the terms and conditions found in any Exhibit and the terms and conditions found in the main body of this
Agreement, the terms and conditions found in the main body of this Agreement shall control. 
  

	13.	 Vendor Compliance with CVS Ethical Standards 

CVS requires Vendor (i) to conduct business with CVS in accordance with CVS’s established legal and ethical standards, routines and
procedures (collectively, “Ethical Standards”) and (ii) to refrain from requesting any impermissible favors, allowances or accommodations from CVS or any of its directors, officers, employees or agents. The Ethical Standards, as may
be updated by CVS from time to time, in its sole discretion, can be found at www.cvssuppliers.com. Vendor, at its sole cost and expense, acknowledges and agrees that it shall, as promptly as practicable following the effective date hereof, provide a
copy of the Ethical Standards (and any amendments or restatements thereof) to each of its employees, agents and subcontractors who are responsible for either managing a CVS account or providing products or services to CVS or any affiliate of CVS, in
each such case whether hereunder or otherwise. 
 [THE NEXT PAGE IS THE SIGNATURE PAGE] 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their respective duly authorized officers or agents as of
the date first above written. 

									
	CVS Pharmacy, Inc.	 		 	LumiraDx Inc.
					
	By:	 	 /s/ Eva Boratto
	 		 	By:	 	 /s/ Dorian LeBlanc

	Name:	 	Eva Boratto	 		 	Name:	 	Dorian LeBlanc
	Title:	 	EVP & CFO	 		 	Title:	 	Chief Financial Officer
	Date:	 	August 18, 2020	 		 	Date:	 	August 17, 2020

 EXHIBIT A 

PRODUCT AVAILABILITY 
 Subject to Vendor
obtaining appropriate FDA Approvals for the LumiraDx Instrument and COVID-19 Test Strips and the other terms and conditions set forth in the Agreement, CVS shall be entitled to purchase LumiraDx Instruments, COVID-19 Test Strips and Ancillary Equipment in monthly amounts no less than what is outlined below. Failure to order any Product type for a designated month shall mean such Product type is no longer required to be
held by Vendor for supply to CVS for that month and such quantities shall not roll over to the following month. CVS shall not be obligated to order or accept any LumiraDx Instrument where the COVID-19 Test
Strip allocation is less than [***] COVID-19 Test Strips per month per LumiraDx Instrument. 
  

													
	 	  	August	 	September	 	October	 	November	 	December	 	January
	 LumiraDX Instrument Allocation
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Install Base
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 COVID-19 Test Strip Allocation
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
							
	 Strips per Machine, per month
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 Strips per Machine, per day
	  	[***]	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 [***] 
 [***]. 

[***]. 

 EXHIBIT B 

PRODUCT PRICING 
 Pricing applicable as per
the below list. Pricing for additional products or product combinations or pooling of strips shall be discussed and agreed mutually between the parties based on cost allocation, reimbursement in place and other agreed factors. 

 

							
	 Product
	  	Pack Size	  	Pricing	 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
			
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 
	 [***]
	  	[***]	  	 	[***	] 

 [***]. 
  

	
	 Products are for professional use (except if specifically
indicated on product otherwise)
  
 LumiraDx and Flame logo are protected trademarks of
LumiraDx. CVS makes no claim to LumiraDx Intellectual Property Rights.
  
 The use of
the LumiraDx Instrument and COVID-19 Test Strips shall be subject to the requirements and specifications as per the Manual, labelling and product specifications. LumiraDx Software for use of the LumiraDx
Instrument is subject to the terms of the End User License Agreement as per attached Exhibit C, which shall apply to CVS and any of its Users (as defined therein). Use of LumiraDx Connect Manager or EHR Connect shall be subject to further license
requirements to be agreed between the Parties.

 EXHIBIT C 

LUMIRADX INSTRUMENT END USER LICENSE AGREEMENT 

PLEASE READ THIS END USER LICENSE AGREEMENT (THIS “AGREEMENT”) BEFORE USING ANY LICENSOR TECHNOLOGY (AS DEFINED BELOW). BY ACCEPTING THIS AGREEMENT,
EITHER BY CLICKING OR TAPPING A BUTTON INDICATING YOUR ACCEPTANCE, EXECUTING AN ORDER FORM OR OTHER DOCUMENT THAT REFERENCES THIS AGREEMENT OR USING ANY LICENSOR TECHNOLOGY, YOU AGREE TO THIS AGREEMENT WITH LUMIRADX UK LTD FOR AND ON BEHALF OF ITS
AFFILIATES (“LICENSOR”). IF YOU ARE ENTERING INTO THIS AGREEMENT ON BEHALF OF A COMPANY OR OTHER LEGAL ENTITY, YOU REPRESENT THAT YOU HAVE THE AUTHORITY TO BIND SUCH ENTITY TO THIS AGREEMENT, IN WHICH CASE THE TERM “CUSTOMER”
WILL REFER TO SUCH ENTITY. IF YOU ARE ENTERING INTO THIS AGREEMENT AS AN INDIVIDUAL, YOU REPRESENT THAT YOU ARE A USER (AS DEFINED BELOW), IN WHICH CASE THE TERM “CUSTOMER” WILL REFER TO YOU AS AN INDIVIDUAL. IF YOU DO NOT HAVE SUCH
AUTHORITY (IF YOU REPRESENT AN ENTITY), OR IF YOU DO NOT AGREE WITH THIS AGREEMENT, YOU MUST NOT ACCEPT THIS AGREEMENT AND MAY NOT USE ANY LICENSOR TECHNOLOGY. 

1.    Definitions. For all purposes of this Agreement, the terms defined below, when used with initial capital letters, will have
the following meanings: 
 (a)     “Documentation” means the physical and electronic documentation provided by
Licensor in conjunction with the Instrument (including the Software). 
 (b)    “Instrument” means the
diagnostic instrument(s) provided by Licensor to Customer. 
 (c)    “Licensor Technology” means the
Instrument (including the Software) and Documentation. 
 (d)    “Patients” means individuals accessing
medical services or care. 
 (e)    “Software” means the proprietary computer software program(s) as embedded
in or installed on the Instrument, and any Updates thereto as delivered to Customer by Licensor under this Agreement, expressly excluding any third party software. 

(f)    “Updates” mean maintenance releases, bug fixes, technological fixes, feature enhancements or
improvements, theme upgrades and other changes made to and entirely new versions of the Software. 

(g)    “Users” means individuals who (i) are 18 years of age or older, (ii) suitably qualified and
trained healthcare professionals and (iii) in the event Customer is an entity, an authorized employee, employee or contractor engaged by an entity managed by Customer, or healthcare professional otherwise engaged by Customer, or, in the event
Customer is an individual, an authorized employee or independent contractor of a purchaser of an Instrument. 
 2.    License
Grant and Restrictions. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Customer a non-exclusive, non-transferable, non-sublicensable limited right and license: to have Users operate the Instrument and Software in accordance with Documentation solely to provide medical services, including medical diagnostics, or care to Patients.
Customer will not and will not permit any third party to: (a) permit any individual other than a User to access or operate the Instrument (including the Software); (b) distribute the Licensor Technology, or any copy thereof, or sublicense or
make it available for use by anyone (other than Users, if Customer is an entity); (c) transfer or sell the Licensor Technology 

 
to any third party; (c) remove, obliterate, obscure, or conceal the proprietary notices or legends which appear on the Licensor Technology; (e) alter, modify, adapt or create derivative
works from the Licensor Technology; (f) decompile, disassemble, translate, or otherwise reverse engineer the Licensor Technology or any part thereof; (g) circumvent any technical limitations of the Licensor Technology or access otherwise
disabled features or functionalities thereof; (h) interfere with the proper working of the Licensor Technology or (i) share or publish the results of any benchmarking or performance testing, and/or compatibility analysis of the Licensor
Technology without Licensor’s prior written consent. 
 3.    Obligations of Customer. 

(a)    Compliance with Laws. Customer will, and if Customer is an entity will cause Users to, comply with all laws
(including federal, state and local laws and regulations, orders and ordinances) now or hereafter enacted, of any jurisdiction in which performance occurs or may occur hereunder. Without limitation, Customer hereby acknowledges that the rights and
obligations of this Agreement are subject to the laws and regulations of the United States relating to the export of products and technical information, and Customer will comply with all such laws and regulations. Customer will not export the
Software under any circumstances. Customer will be solely responsible for its violations of any of the foregoing. 

(b)    Training. The Documentation includes a user manual that provides basic training information for Users.
Customer will implement appropriate controls to ensure that only Users operate the Instrument (including the Software) and that all Users have read and understand the Documentation prior to using the Instrument. Licensor has no obligation to provide
any installation, training, customization, support, maintenance or other services with respect to the Licensor Technology except as may be provided in a separate written agreement signed by a duly authorized officer of Licensor. 

4.    Disclaimers. TO THE FULLEST EXTENT ALLOWED BY LAW, (I) EXCEPT AS SET FORTH IN THE PURCHASE AGREEMENT, LICENSOR DOES NOT
MAKE ANY ADDITIONAL WARRANTIES, WHETHER EXPRESS OR IMPLIED, CONDITIONS, OR REPRESENTATIONS TO CUSTOMER, ANY OF ITS AFFILIATES OR ANY OTHER PARTY WITH RESPECT TO THE LICENSOR TECHNOLOGY OR OTHERWISE REGARDING THIS AGREEMENT, WHETHER ORAL OR WRITTEN,
EXPRESS, IMPLIED, OR STATUTORY; AND (II) THE LICENSOR TECHNOLOGY IS PROVIDED “AS IS” AND “AS AVAILABLE” INCLUDING WITH ALL FAULTS AND ERRORS AS MAY OCCUR THEREIN. WITHOUT LIMITING THE FOREGOING, ANY WARRANTY, CONDITION, OR
REPRESENTATION, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WITH RESPECT TO OPERABILITY, USE, ACCURACY, VALIDITY, MERCHANTABILITY, SATISFACTORY QUALITY, TITLE, NONINFRINGEMENT, OR FITNESS FOR A PARTICULAR PURPOSE, ARE EXPRESSLY EXCLUDED AND
DISCLAIMED. LICENSOR DOES NOT WARRANT THAT THE LICENSOR TECHNOLOGY WILL MEET THE CUSTOMER’S REQUIREMENTS OR EXPECTATIONS, OR THAT THE LICENSOR TECHNOLOGY WILL OPERATE UNINTERRUPTED OR ERROR-FREE. THE USE OF THE LICENSOR TECHNOLOGY IS AT THE
SOLE DISCRETION AND RISK OF THE CUSTOMER AND/OR ITS EMPLOYEES, AGENTS, SUBCONTRACTORS, SUCCESSORS, AND ASSIGNS. LICENSOR DOES NOT MAKE ANY WARRANTIES REGARDING THIRD PARTY SOFTWARE (INCLUDING OPEN SOURCE SOFTWARE). CUSTOMER ACKNOWLEDGES AND AGREES
THAT THE TERMS OF A THIRD PARTY SOFTWARE LICENSE MAY OVERRIDE SOME OF THE TERMS OF THIS AGREEMENT. Some states may not allow the exclusion or limitation of warranties, so the above limitation or exclusion may not apply to you. This Agreement gives
Customer specific legal rights and obligations, and Customer may also have other legal rights or obligations which vary from state to state. CUSTOMER ASSUMES SOLE RESPONSIBILITY FOR RESULTS OBTAINED FROM THE USE OF THE LICENSOR TECHNOLOGY AND FOR
CONCLUSIONS DRAWN FROM SUCH USE. CUSTOMER ACKNOWLEDGES THAT THE LICENSOR TECHNOLOGY 

 
WAS NOT DESIGNED TO CUSTOMER’S REQUIREMENTS AND THAT IT IS CUSTOMER’S RESPONSIBILITY TO ENSURE THAT THE LICENSOR TECHNOLOGY AS DESCRIBED IN THE DOCUMENTATION MEETS ITS REQUIREMENTS. THE
LICENSOR TECHNOLOGY IS INTENDED ONLY AS A DIAGNOSTIC AID AND IS NOT A SUBSTITUTE FOR THE EXPERTISE AND JUDGEMENT OF PHYSICIANS OR OTHER HEALTHCARE PROFESSIONALS. ALL INFORMATION IS PROVIDED ON THE BASIS THAT THE HEALTHCARE PROFESSIONALS RESPONSIBLE
FOR PATIENT CARE WILL RETAIN FULL AND SOLE RESPONSIBILITY FOR DECIDING ANY CARE OR TREATMENT TO PRESCRIBE OR DISPENSE FOR ALL PATIENTS AND IN PARTICULAR WHETHER THE USE OF INFORMATION PROVIDED BY THE LICENSOR TECHNOLOGY IS SAFE, APPROPRIATE OR
EFFECTIVE FOR ANY PARTICULAR PATIENT OR IN ANY PARTICULAR CIRCUMSTANCES. 
 5.    Limitation of Liability. LICENSOR’S AND
ITS THIRD-PARTY VENDORS’ MAXIMUM TOTAL LIABILITY FOR ALL MATTERS ARISING UNDER OR RELATED TO THIS AGREEMENT, REGARDLESS OF THE FORM OF ACTION, IN CONTRACT, TORT OR OTHERWISE, WILL NOT EXCEED [***]. IN ANY EVENT, NEITHER LICENSOR NOR ANY OF ITS
THIRD-PARTY VENDORS WILL UNDER ANY CIRCUMSTANCES BE LIABLE FOR ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR OTHER INDIRECT DAMAGES IN CONNECTION WITH ANY MATTER ARISING UNDER OR RELATED TO THIS AGREEMENT, EVEN IF LICENSOR WAS AWARE OF THE
POSSIBILITY OF SUCH DAMAGES. Some states may not allow the exclusion or limitation of liability or certain damages, so the above limitation or exclusion may not apply to Customer. This Agreement gives Customer specific legal rights and obligations,
and Customer may also have other legal rights or obligations which vary from state to state. 
 6.    Reservation of Rights and
Ownership. The Licensor Technology and all proprietary and intellectual property rights therein are at all times the property of Licensor, and Customer will have no right, title or interest therein except as expressly provided herein. Any rights not
expressly granted in Section 2 above are reserved by Licensor. The Licensor Technology is the proprietary and confidential property of Licensor. Customer will keep confidential the Licensor Technology and will not, and if Customer is an entity
will cause Users not to, use any part of the Licensor Technology in any manner other than as expressly authorized under this Agreement, in accordance with the procedures and guidelines set forth in the Documentation, or otherwise in writing by
Licensor. If Customer is an entity, Customer is liable for any of its User’s breach or non-compliance. 

7.    Term and Termination. The Licensor Technology is licensed to Customer during the time the Instruments are used by Customer,
subject to termination as set forth herein. Licensor may terminate this Agreement in whole or in part by written notice to Customer, in the event of the occurrence of any of the following: (a) if Customer, or if Customer is an entity any of its
Users, uses, reproduces, distributes or sublicenses, as applicable, any of the Licensor Technology in any manner not authorized herein; (b) if Customer or any of its Users (if applicable) transfers or allows any third party (other than such
Users) to access or operate any Instrument without Licensor’s prior written consent; (c) if Customer or any of its Users (if applicable) breaches this Agreement (other than as set forth in the foregoing clauses (a) or (b)) and does
not cure such breach within 14 days after written demand by Licensor; or (iv) if Customer makes a general assignment for the benefit of creditors, or files a voluntary petition in bankruptcy or for reorganization or arrangement under the
bankruptcy laws, or if a petition in bankruptcy is filed against Customer and is not dismissed within 30 days after the filing, or if a receiver or trustee is appointed for all or any part of the property or assets of Customer. Upon any termination
of this Agreement the license granted under this Agreement will terminate, and Customer will immediately (i) cease all use of the Licensed Technology, (ii) destroy all copies of the Documentation and (iii) delete or remove all patient
data or other personal data from the Software. Upon such termination, all rights and obligations of the parties under this Agreement will cease except that the provisions of Sections 4 through 8 (inclusive) will survive. 

 8.    General. Customer may not assign this Agreement, or sublicense any of the
rights granted herein, in whole or in part, without the prior written consent of Licensor, which consent may be withheld at the sole discretion of Licensor. Any attempted assignment, delegation or transfer in violation hereof will be null and void.
Subject to the foregoing, this Agreement will be binding on the parties and their successors and assigns. This Agreement contains the entire understanding of the parties about its subject. It supersedes and replaces all prior or contemporaneous
understandings or agreements, written or oral, regarding such subject matter, and prevails over any conflicting terms or conditions contained on printed forms submitted with purchase orders, sales acknowledgments or quotations. No provision or part
of this Agreement or remedy hereunder may be waived except by a writing signed by a duly authorized representative of the party making the waiver. Any such waiver will be narrowly construed to apply only to the specific provision and under the
specific circumstances for which it was given, and will not apply with respect to any repeated or continued violation of the same provision or any other provision. Failure or delay by either party to enforce any provision of this Agreement will not
be deemed a waiver of future enforcement of that or any other provision. Nothing in this Agreement will be construed to place Licensor and Customer in an agency, employment, franchise, joint venture, or partnership relationship. Neither party will
have the authority to obligate or bind the other in any manner, and nothing herein contained will give rise or is intended to give rise to any rights of any kind to any third parties. Neither party will represent to the contrary, either expressly,
implicitly or otherwise. In the event that any provision of this Agreement is found to be unenforceable, such provision will be reformed only to the extent necessary to make it enforceable, and such provision as so reformed will continue in effect,
to the extent consistent with the intent of the parties as of the effective date hereof. If any provision or part of this Agreement will, to any extent, be or become invalid, illegal or unenforceable, the remainder of this Agreement will continue in
effect, and every other provision of this Agreement will remain valid and enforceable to the full extent permitted by applicable law. In such event, the invalid or unenforceable provision will be reformed only to the extent necessary to make it
enforceable, and such provision as so reformed will continue in effect, to the extent consistent with the intent of the parties as of the effective date hereof. This Agreement is made under and will be governed by and construed in accordance with
the laws of the State of New York, without regard to its conflict of laws principles, and specifically excluding from application to this Agreement the United Nations Convention on the International Sale of Goods.EX-10.13

 Exhibit 10.13 

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be 

competitively harmful if publicly disclosed. Information that was omitted has been noted in this 

document with a placeholder identified by the mark “[***]”. 

         FLEXTRONICS CONFIDENTIAL 
 Flextronics Manufacturing
Services Agreement 
 This Flextronics Manufacturing Services Agreement (“Agreement”) is entered into this 18th” day of October 2017 and is effective as of October 18, 2017 (the “Effective Date”) by and between LumiraDx UK Limited, having its registered address at 3 More London
Riverside, London, SE1 2AQ, England (“LumiraDx”), and Flextronics Medical Sales and Marketing, Ltd., having its place of business at [***] (“Flextronics”). 

LumiraDx desires to engage Flextronics to perform manufacturing services as further set forth in this Agreement and in applicable agreed upon Specifications
to be attached or incorporated by reference. The parties agree as follows: 
  

	1.	 DEFINITIONS 

In addition to terms defined elsewhere in this Agreement, the definitions referred to in Exhibit 1 apply herein, unless the context requires otherwise. 

 

	2.	 MANUFACTURING SERVICES 

 

	 	2.1.	 Services and Specifications. 

(a)    Subject to the terms and conditions of this Agreement, LumiraDx hereby engages Flextronics to procure Materials, and
to manufacture, assemble, test and supply Products pursuant to mutually agreed upon written Specifications (collectively, such work, the “Services”). In case of any conflict between the Specifications and this Agreement, this
Agreement shall prevail. 
 (b)    Flextronics and LumiraDx shall maintain and update the Specifications in accordance
with the terms of this Agreement. 
 (c)    Prior to commencing manufacturing of the Products, Flextronics shall provide
Lumira Dx with information setting out all Materials to be used in the production process together with a description of the production process. If a change to the Specifications is required by applicable Laws, LumiraDx shall inform Flextronics and
the parties shall jointly agree in good faith a plan for implementing any changes so required as well as the new Fee List relating thereto. 

2.2.    Supplier Obligations. Flextronics shall manufacture and supply each Product in accordance with the
Compliance Requirements. 
 2.3.    Engineering Changes. Either party may request that Flextronics
incorporate engineering changes to the Product or Specifications by providing a written description of the proposed engineering change sufficient to permit the parties to evaluate the feasibility and cost of the proposed change to the other party
for approval. Any proposed engineering change must comply with the Compliance Requirements, and be approved by LumiraDx. Flextronics shall proceed with the proposed engineering changes when the parties have agreed upon the changes to the
Specifications, delivery schedule and adjustments to the Fee List and reimbursement of any implementation costs incurred by Flextronics and any adjustment to Product pricing, as applicable. 

2.4.    Tooling; Non-Recurring Expenses; Software. LumiraDx shall
pay for or obtain and provide to Flextronics any Product-specific tooling, equipment or software and other reasonably necessary non-recurring expenses as set forth in Flextronics’s pricing quotations.
Such equipment shall remain the property of LumiraDx and shall be returned to Lumira Dx upon LumiraDx’s request on termination of this Agreement in accordance with its terms, and Flextronics warranty obligations shall automatically expire at
the same time. 
 2.5.    Labelling Subject to labelling approval from the governmental authority with
competent jurisdiction for the Product in each jurisdiction in which it is to be distributed, Flextronics shall supply the Products to LumiraDx using LumiraDx’s labelling and packaging design. LumiraDx shall ensure the accuracy of all labels
and packaging used on the Products and any leaflets accompanying the Products and that the leaflets and packaging comply with Compliance Requirements. Should LumiraDx inform Flextronics that changes to the leaflet or packaging are required for the
Products to comply with the Compliance Requirements, including any mandatory changes under applicable Laws, Flextronics shall make such changes at the cost of LumiraDx. 

  
 - 1 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

	3.	 FORECASTS; ORDERS; FEES; PAYMENT 

3.1.    Forecast and Purchase Orders. LumiraDx shall provide Flextronics, on a [***] basis, a rolling [***]
forecast indicating LumiraDx’s monthly Product and Services requirements (the “Forecast”). Unless a different timeframe is agreed to by the parties, LumiraDx shall on a [***] basis provide purchase orders for the first three
(3) month of the then-applicable Forecast and LumiraDx agrees to purchase the amount of Products set out in such purchase order. The purchase orders are to be sent to Flextronics in writing. Flextronics shall inform LumiraDx about the Materials
Procurement Lead Time on a quarterly basis. 
 3.2.    Purchase Orders; Precedence. As a matter of
convenience, LumiraDx may use its standard purchase order form for any orders provided for hereunder. The terms and conditions contained in this Agreement prevail over any terms and conditions of any such purchase order, acknowledgment form or other
form instrument exchanged by the parties, and no additional, contradictory, modified or deleted terms established by such instruments are intended to have any effect on the terms of this Agreement, even if such instrument is accepted by the other
party. 
 3.3.    Purchase Order Acceptance. Flextronics shall normally accept purchase orders from
LumiraDx, provided that Flextronics may reject any purchase order: (a) that is for a change in previously ordered quantities that has not been approved in advance by Flextronics; (b) if the fees reflected in the purchase order are
inconsistent with the parties’ then-current agreement with respect to fees; (c) that represents a significant deviation from the Forecast for the same period, unless such deviation is approved by Flextronics; (d) if the parties have
not agreed on changes to the Fee List made in accordance with Section 3.4(c); or (e) that would extend Flextronics financial exposure beyond LumiraDx’s approved credit line. Flextronics shall notify LumiraDx of rejection of any
purchase order within [***] of receipt of such purchase order. 
  

	 	3.4.	 Fees; Changes; Taxes. 

(a)    LumiraDx shall purchase the Products at the relevant price as set out in the Fee List which is attached hereto as
Exhibit 3 and incorporated herein by reference. Prices in the Fee List are based on delivery FCA (lncotems 2010) except as provided in this Agreement. All costs of the supply chain or distribution, of the Products shall be included in the Prices set
out in the Fee List. The cost of Materials and Production Materials are included in the price set out in the Fee List. 

(b)    The initial fees shall be as identified in the Fee List. If a Fee List is not attached or completed or amended as
agreed upon, then the initial fees shall be as set forth in purchase orders issued by LumiraDx and accepted by Flextronics in accordance with the terms of this Agreement. 

(c)    The Fee List shall be reviewed and adjusted to the currency exchange rates at least quarterly by the parties. Any
other changes to the Fee List (including, without limitation, engineering related changes set forth in Section 2.3) shall be agreed by the parties biannually, such agreement not to be unreasonably withheld or delayed. The parties agree that it
shall be considered reasonable, and the fees may be increased or decreased if the market price of fuels, Materials, equipment, labor and other production costs, increase beyond normal variations in pricing or currency exchange rates as demonstrated
by Flextronics or by LumiraDx. 
 (d)    Without limiting the foregoing, if any taxes, duties, laws, rules, regulations,
court orders, administrative rulings or other governmentally-imposed or governmentally-sanctioned requirements (including mandatory wage increases) result in changes to the costs of performance of any Services hereunder (a “Governmental
Change”), then the parties shall, as soon as possible following the identification of such Governmental Change, agree on and implement revised prices to reflect such Governmental Change, retroactive to the date on which the
Governmental Change became effective. 
 (e)    LumiraDx is responsible for additional fees and costs due to:
(i) changes to the Specifications, to the projected volumes, minimum run rates, or to any incorrect assumptions set forth in Flextronics’s quotation and not corrected by LumiraDx; (ii) a Governmental Change; (iii) failure of
LumiraDx or its subcontractor to timely provide sufficient quantities or a reasonable quality level of LumiraDx Controlled Materials where applicable to sustain the production schedule; and (iv) any
pre-approved expediting charges reasonably necessary because of a change in LumiraDx’s requirements. 

(f)    All fees are exclusive of (i) Taxes, (ii) amounts related to the export licensing of the Product and payment
of brokers fees, duties, tariffs or similar charges, and (iii) NRE Charges, and LumiraDx shall be responsible for all such items. 

 3.5.    Currency and Exchange Rates. Unless otherwise
agreed in writing, the Fees List shall be based on the exchange rate(s) for converting non-U.S. Dollar Inventory purchases into U.S. Dollars. The fees shall be adjusted with a debit/credit memo on a quarterly
basis, in accordance with Section 3.4(c), based on the cumulative changes in the exchange rate(s) from month to month in the previous quarter. The three (3) monthly exchange rate variances are calculated using the Bloomberg Professional
Service® exchange rates on the last Business Day of each month. 
 3.6.
    Payment. 
 (a)    Flextronics shall invoice LumiraDx monthly for the Products
provided in the previous month. 
 (b)    LumiraDx shall notify Flextronics in writing of any dispute with any invoice
(along with substantiating documentation and a reasonably detailed description of the dispute) within [***] from its receipt of such invoice. LumiraDx will pay all undisputed amounts under such invoice within the period set out in
Section 3.6(c). The parties shall seek to resolve any such disputes expeditiously and in good faith. If the dispute is not resolved by the parties in [***], either party may invoke the dispute resolution procedure in Section 12, and
Flextronics may, by written notice, in its sole discretion, immediately stop all Services until the earlier of (1) the full payment of the disputed invoice, or (2) the dispute is resolved by the agreement of the parties or by the decision
of the arbitration under Section 12. LumiraDx shall be entitled to make the payment of any disputed invoice to continue Services, subject to a decision in arbitration under Section 12 deciding on the dispute. The payment to continue
Services will not affect any of LumiraDx’s right to continue the dispute. 
 (c)    LumiraDx shall pay all amounts
due in U.S. Dollars within [***] of the date of the invoice to the account specified in that invoice. The payment term shall be reviewed on an annual basis and adjusted upon the mutual consent of the parties. 

(d)    If LumiraDx fails to pay amounts due in accordance with the foregoing, LumiraDx shall pay one of [***] interest on
all late payments. Furthermore, if LumiraDx is late with payments or Flextronics has reasonable cause to believe based on evidence or documentation submitted that LumiraDx may not be able to pay, then Flextronics may by written notice, in its sole
discretion, undertake any or any combination of the following: (i) stop all Services under this Agreement until assurances of payment satisfactory to Flextronics are received or payment is received; (ii) demand prepayment for purchase
orders; (iii) delay shipments; and (iv) to the extent that Flextronics’s personnel cannot be reassigned to other billable work during such stoppage or in the event restart cost are incurred, invoice LumiraDx for additional fees before
the Services can resume. LumiraDx agrees to provide all reasonably necessary financial information required by Flextronics from time to time, in order to make a proper assessment of the creditworthiness of LumiraDx. However once LumiraDx Limited is
admitted to trading on a regulated market, (Admission), LumiraDx will not be under any obligation to provide financial information other than that which is publicly available and Flextronics acknowledges that it will have to rely on such
publicly disclosed information only. 
 3.7.     Credit Terms/Security Interest. Flextronics shall provide
LumiraDx with an initial credit limit, which shall be reviewed (and, if necessary, adjusted) periodically, but not more than once in every quarter. LumiraDx shall provide information reasonably requested by Flextronics, in support of such credit
reviews. In Flextronics’ reasonably exercised discretion and based upon reasonably complete financial information, Flextronics shall have the right to reduce LumiraDx’s credit limit and/or require LumiraDx to obtain an escrow account; in
such case, the bank chosen by LumiraDx shall be reasonably acceptable to Flextronics, the escrow account shall be in force for a minimum period of time of [***] and shall be in an amount equal to Flextronics’s entire exposure, including without
limitation the risks associated with Inventory, Special Inventory, and the accounts receivable from LumiraDx in accordance with LumiraDx’s forecasts. Alternatively, LumiraDx may, in its sole discretion, prepay an amount equal to the relevant
price in the Fee List for Products ordered in the Forecast in substitution for its obligation to provide an escrow account, subject to LumiraDx settling all of due or past due invoices Flex issued earlier based on this Agreement (including but not
limited to the accounts receivables for the Products, Inventory, Special Inventory or Monthly Charges). The prepayment is to be made within [***] from the date of acceptance of the purchase order. Notwithstanding the foregoing, nothing in this
clause 3.7 shall oblige LumiraDx to provide any financial information to Flextronics that is not generally available to the public after the Admission of LumiraDx Limited. The draw down procedures under the escrow account shall be agreed between
Flextronics and LumiraDx. Flextronics shall have the right to suspend performance (e.g., cease ordering Materials based on LumiraDx’s Forecast and/or cease making Product deliveries) until LumiraDx either makes a payment to bring its account
within the revised credit limit and/or makes other arrangements satisfactory to Flextronics. Flextronics shall have the right to retain ownership in the Products until LumiraDx has paid for the Products and all Product-related charges to the extent
such Products remain within the control of LumiraDx. 

	4.	 MATERIALS PROCUREMENT; LUMIRADX RESPONSIBILITY FOR MATERIALS 

4.1.    Authorization to Procure Materials. Inventory and Special Inventory. LumiraDx’s accepted
purchase orders and each Forecast shall constitute authorization for Flextronics to procure, without LumiraDx’s prior approval: 

(a)    Inventory to manufacture the Products covered by such purchase orders and Forecasts based on the applicable Lead
Times; and 
 (b)    Minimum Order Inventory reasonably required to support LumiraDx’s purchase orders and
Forecasts; and 
 (c)    Any other Special Inventory which is separately authorized by LumiraDx. 

4.2.    Supply Chain Management. 

(a)    Purchases from AVL. LumiraDx shall provide to Flextronics and maintain an Approved Vendor List.
Flextronics shall only purchase from vendors on a current AVL the Materials required to manufacture the Product. LumiraDx shall include Flextronics on AVLs for Materials that Flextronics can supply if such products are considered suitable by
LumiraDx and, if Flextronics is competitive with other vendors with respect to reasonable and unbiased criteria for acceptance established by LumiraDx, LumiraDx shall raise no objection to Flextronics sourcing Materials from itself. For purposes of
this Section 4.3 only, the term, “Flextronics” includes any Flextronics Affiliate. 

(b)    LumiraDx Controlled Materials. LumiraDx may direct Flextronics to purchase LumiraDx Controlled
Materials in accordance with the LumiraDx Controlled Materials Terms. LumiraDx acknowledges that the LumiraDx Controlled Materials Terms may directly impact Flextronics’s ability to perform, under this Agreement and to provide LumiraDx with the
flexibility LumiraDx is requiring pursuant to the terms of this Agreement. In the event that Flextronics reasonably believes that LumiraDx Controlled Materials Terms shall create an additional cost that is not covered by this Agreement, then
Flextronics shall notify LumiraDx and the parties shall agree to either (i) compensate Flextronics for such additional costs, (ii) amend this Agreement to conform, to the LumiraDx Controlled Materials Terms or (iii) amend the LumiraDx
Controlled Materials Terms to conform, to this Agreement, in each case at no additional charge to Flextronics. LumiraDx agrees to provide copies to Flextronics of all LumiraDx Controlled Materials Terms upon the execution of this Agreement and
promptly upon execution of any new agreements with vendors. LumiraDx agrees not to make any modifications or additions to the LumiraDx Controlled Materials Terms or enter into new LumiraDx Controlled Materials Terms with vendors that shall
negatively impact Flextronics’s procurement activities without giving prior notice to Flextronics. 
  

	 	(c)	 In performing its obligations under the agreement, Flextronics shall: 

(i)    comply with all applicable anti-slavery and human trafficking laws, statutes, regulations and codes
from time to time in force including but not limited to the Modern Slavery Act 2015; 
 (ii)    have and
maintain throughout the term of this Agreement its own policies and procedures to ensure its compliance and allow LumiraDx access to such policies upon receiving a request from LumiraDx to do so; and 

(iii)    not engage in any activity, practice or conduct that would constitute an offence under sections 1,
2 or 4, of the Modem Slavery Act 2015 if such activity, practice or conduct were carried out in the UK; 

(iv)    act in compliance with all Anti-Bribery Laws; 

(v)    have and maintain in place Adequate Procedures; 

(vi)    promptly report to LumiraDx any request or demand for undue financial or other advantage of any
kind received by Flextronics in connection with the performance of this Agreement; 
 (vii)    provide
LumiraDx with an annual written certification signed by a Representative of Flextronics that it and its Representatives and Associated Persons have complied with this Section 4.3(c); and 

(viii)    ensure that any Affiliate with it who is performing services in connection with the subject
matter of this Agreement are required to abide by terms equivalent to those agreed by Flextronics in this Section. Flextronics shall be responsible for such persons’ compliance with this Section and shall be liable to LumiraDx for any breach by
that person of this Section. 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 Breach of this Section is a material breach of this Agreement. 

(d)    Flextronics shall endeavor to obtain assurance from the suppliers (except Suppliers designated by LumiraDx as set
out in Section 6.2 (I) of this Agreement) about their compliance with Section 4.3 (c) and shall make reasonable efforts to include inspection of it in the scope of the suppliers· audits conducted by Flextronics. 

4.3.    Flextronics shall be entitled to sub-contract all or any part of the
manufacturing of the Products to such persons as it thinks fit and to any of its Affiliates, unless LumiraDx object to the engagement of a sub-contractor due to
non-compliance with the Compliance Requirements. Flextronics shall use commercially reasonable efforts to impose such terms and conditions on sub-contractor or
Affiliates that are substantially similar to the terms and conditions of this Agreement. However, Flextronics will remain solely responsible to LumiraDx for the performance of any such sub-contractors and will
be liable to LumiraDx for any breach of this Agreement. For the avoidance of doubt, for the purpose of this Agreement, Material vendors shall not be considered as sub-contractors. 

 

	5.	 SCHEDULE CHANGE, CANCELLATION, STORAGE 

 

	 	5.1.	 Quantity Increases and Shipment Schedule Changes. 

(a)    For any accepted purchase order or Forecast, LumiraDx may request an increase in the quantity of Products ordered or
forecast. All Product quantity increases require Flextronics’s approval, which, acting in good faith but in its sole discretion, may or may not be granted. Flextronics shall use reasonable commercial efforts to meet any allowed Product quantity
increases, which are subject to Materials and capacity availability. If Flextronics agrees to such increase in the quantity, and if there are extra costs to meet such increase, then LumiraDx shall be liable for such extra costs. 

(b)    For any accepted purchase order, LumiraDx may request a reschedule of the expected delivery date not to exceed
[***] from the originally agreed date in the purchase order. All Product reschedules in excess of [***] require Flextronics’s approval, which, acting in good faith but, in its sole discretion, may or may not be granted. If Flextronics agrees to
accept a reschedule of any length of time, and if there are extra costs to meet such reschedule or increase, then LumiraDx shall be liable for such extra costs. Any part of a purchase order quantity that is rescheduled pursuant to this
Section 5 may not be subsequently rescheduled (except with the approval of Flextronics). 
 (c)    Any delays in
the normal production or interruption in the workflow process caused by LumiraDx’s changes to the Specifications or failure to provide sufficient quantities or a reasonable quality of LumiraDx Controlled Materials where applicable to sustain
the production schedule, shall be considered a reschedule of any affected purchase orders for purposes of this Section for the period of such delay. 

(d)    Products that have been ordered by LumiraDx and that have not been picked up in accordance with the agreed upon
shipment dates shall be considered cancelled and LumiraDx shall be responsible for such Products in the same manner as set forth in Section 5.2. LumiraDx agrees that Flextronics shall have the right to invoice it for all cancelled Products and
agrees to provide Flextronics, within [***] following the invoice, the location to which Flextronics shall ship the Products. 

(e)    Flex shall inform LumiraDx about any issues with the supply chain as soon as possible after being aware of it, if
it might affect the shipment dates. In case of late delivery within Flex’s control, Flextronics shall be required to expedite delivery of the Products to LumiraDx as soon as reasonably possible., In case of a delay within Flex’s control of
more than [***] the parties shall discuss in good faith any action to be undertaken, including replacement, or alternative supply The Parties shall cooperate in good faith to stop in any delay in supply as soon as reasonably possible. 

(I)    Cancellations. LumiraDx may not cancel, except as provided in Section 5.1 above, all or any portion of Product
quantity of an accepted purchase order without Flextronics’ prior written approval, which, in its sole discretion, may or may not be granted. If LumiraDx does not request prior approval or if LumiraDx and Flextronics do not agree in writing to
specific terms with respect to any approved cancellation, then LumiraDx shall pay Flextronics Monthly Charges for any such cancellation, calculated as of the first day after such cancellation for any Product or Inventory or Special Inventory
procured by Flextronics to support the original delivery schedule. In addition, if Flextronics notifies LumiraDx that any Product (or partially completed Product) subject to such cancellation has remained in Flextronics’s possession for more
than [***], then LumiraDx shall immediately purchase from Flextronics such Product at the amount set forth in the Fee List (or a pro-rata proportion thereof for any applicable partially completed Product).

  
 - 5 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

	 	5.2.	 Excess. Aged, and Obsolete Inventory: 

 

	 	(a)	 LumiraDx shall be responsible for the following: 

 

	 	(i)	 Excess Inventory. 

A.    Carrying Charges. At the end of every quarter, Flextronics shall report the Excess Inventory. Such Excess
Inventory reports shall normally be deemed agreed to by LumiraDx, unless LumiraDx provides a written objection within [***] of the end of the corresponding quarter. LumiraDx shall pay Flextronics a carrying cost fee equal to the [***]. 

B.    Purchase of Excess Inventory. At the end of every quarter, LumiraDx shall purchase Excess Inventory that has been
Excess Inventory for at least [***], as identified by Flextronics in each quarterly report, at a price equal to [***]. 

(ii)    Obsolete Inventory. At the end of every quarter Flextronics shall report the Obsolete Inventory.
LumiraDx’s failure to object to Flextronics’s Obsolete Inventory report (or failure to deny its responsibility for such inventory) shall constitute its acceptance of Flextronics’s Obsolete Inventory report. After a validation
period, which shall not exceed [***] from the date of such report, LumiraDx shall purchase the Obsolete Inventory at a price equal to (as applicable) [***]. For any Obsolete Inventory that is not purchased by LumiraDx, LumiraDx shall pay Flextronics
a carrying cost fee equal to [***]. 
 (iii)    Aged Inventory. At the end of every quarter, Flextronics shall
report the Aged Inventory. LumiraDx’s failure to object to Flextronics’s Aged Inventory report (or failure to deny its responsibility for such inventory) shall constitute its acceptance of Flextronics’s Aged Inventory report. After
validation, which shall not exceed [***] from the date of such report, LumiraDx shall purchase the Aged Inventory at a price equal to (as applicable) [***]. For any Aged Inventory that is not purchased by LumiraDx, LumiraDx shall pay Flextronics a
carrying cost fee equal to [***].] 
 5.3.    Prior to invoicing LumiraDx for the amounts due pursuant to Sections 5.1,
5.2, [and Section 5.3 (other than the carrying charges for Excess Inventory)] Flextronics shall use commercially reasonable efforts for a period not to exceed [***] from the date of any such reports, to return for refund unused Materials
[from Excess, Obsolete, Aged Inventory and Special Inventory], to cancel pending orders for such inventory, and to otherwise mitigate the amounts payable by LumiraDx. 

5.4.    LumiraDx shall submit payment for the amounts identified and invoiced pursuant to this Section in accordance with
the terms for payment set forth above in Section 3. Flextronics shall ship the [Excess, Obsolete, and Aged Inventory and Special Inventory] to LumiraDx promptly following said payment by LumiraDx In the event LumiraDx does not pay in accordance
with the payment terms set forth above, then, in addition to any late payment charges that Flextronics is due from LumiraDx, Flextronics shall be entitled to dispose of such [Excess, Obsolete, and Aged Inventory and Special Inventory] in a
commercially reasonable manner and credit to LumiraDx any monies received from third parties. 
 5.5.    For changes
(including cancellation and reschedules) that are not consistent with this Section 5, LumiraDx shall be responsible for the following costs in addition to the charges set forth above: 

(a)    any vendor cancellation charges incurred; and 

(b)    expenses incurred by Flextronics related to labor and equipment specifically put in place to support the purchase
orders and Forecasts that are affected by such reschedule or cancellation (as applicable); and 

  
 - 6 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 (c)    the cost of unwinding any currency hedging contracts entered into
by Flextronics that are affected by such reschedule or cancellation (as applicable) (it being understood that Flextronics shall provide LumiraDx with a credit for any gain received by Flextronics as a result of such unwinding). 

5.6.    No Waiver. Flextronics’s failure to invoice LumiraDx for any of the charges set forth in this
Section does not constitute a waiver of Flextronics’s right to charge LumiraDx for the same event or other similar events in the future. 
  

	6.	 SHIPPING TERMS 

6.1.    Shipments. Flextronics shall (a) deliver all Products pursuant to the terms of this Agreement
suitably packed for shipment in accordance with the Specifications and marked for shipment to LumiraDx’s destination specified in the applicable purchase order, and (b) make such deliveries FCA (Free Carrier, lncoterms 2010) Althofen to
(the “Delivery Point”). Delivery of Products shall be completed and title and risk shall pass (in accordance with FCA lncoterms 2010) to LumiraDx after loading the Products on the carrier vehicle at the Delivery Point. All freight,
insurance and other shipping expenses, as well as any special packing expenses not expressly included in the original quotation for the Products, shall be paid by LumiraDx. 

6.2.    Trade Compliance. 

(a)    Neither party shall export, re-export or otherwise transfer any Products,
Materials commodities, software, or technology in connection with performance of this Agreement (individually and collectively, “Technology”) inconsistent with any requirement of the Export Administration Regulations (EAR), the
International Traffic in Arms Regulation (ITAR), or Foreign Assets Control Regulations, or the laws or regulations of the United States and (as applicable) the exporting country outside the U.S. provided, however, in the case of Flextronics, that
LumiraDx provides all information necessary to perform proper export authorization and shall be responsible for the accuracy and completeness of all such information provided by LumiraDx, including: identification of all parties to the transaction,
HTS and ECCN classifications, and any other information relevant to licenses for the Technology. In addition, neither party shall export, re-export or otherwise transfer any Technology to any end-user engaged in, or for any end use related to, directly or indirectly, the design, development, production, use or stockpiling of weapons of mass destruction or the means of delivery thereof (e.g., nuclear,
chemical, biological, etc.). 
 (b)    LumiraDx shall be responsible for obtaining any license, permit or other
governmental approvals (individually and collectively, “Export Licenses”) required for the export, re-export, or transfer of any Technology, and LumiraDx shall inform Flextronics, where
required, when an Export License has been obtained and communicate the terms and conditions of any such Export License to Flextronics. LumiraDx shall be responsible for all reviews, classifications and licenses related to any encryption or other
information security-related regulations (including Encryption Review Requests and Commodity Classification Automated Tracking System numbers), and LumiraDx shall inform Flextronics of the terms and conditions of any applicable restrictions or
licenses related thereto and the authorities from which such restrictions or licenses have been received. 
 (c)    Each
party shall notify the other party as soon as possible of any notification received by it from any governmental authority in relation to the manufacturing of any Product. 

(d)    The parties shall promptly inform each other of any actual or pending change to Compliance Requirements within
their knowledge that may have an impact on the manufacturing of the Products. 
 (e)    To the extent that Products are
imported into any country, LumiraDx shall act as the importer of record. 
 (f)    In the event LumiraDx designates a
supplier (including to Materials vendors, transporters, warehousemen, freight forwarders, and brokers) to be used by Flextronics, then: (i) LumiraDx shall designate only suppliers that comply with the minimum security requirements of applicable
voluntary anti-terrorism security measures (e.g., C-TPAT Customs-Trade Partnership Against Terrorism); (ii) LumiraDx shall prohibit any such suppliers from
sub-contracting to any suppliers that are not in compliance with the aforementioned laws and minimum security requirements; and (iii) LumiraDx shall support Flextronics in determining supplier compliance
with the requirements in this Subsection, including without limitation by requiring suppliers designated by LumiraDx to complete a Flextronics questionnaire and to undergo periodic on-site audits to be
conducted by a provider designated by Flextronics, at LumiraDx’s expense. 

  
 - 7 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

	7.	 PRODUCT ACCEPTANCE AND EXPRESS LIMITED WARRANTY 

7.1.    Product Acceptance. The Products delivered by Flextronics shall be inspected and tested as required
by LumiraDx within [***] of receipt at the “ship to” location on the applicable purchase order. If Products do not conform to the purchase order or the warranty set forth at Section 7.6(a) below LumiraDx has the right to reject such
Products during said period. Products not rejected during said period shall be deemed accepted, it being understood that the rights set out in Section 7.6 (a) shall remain in place. LumiraDx may return defective Products in accordance with the
procedures set forth below. 
 7.2.    If LumiraDx notifies Flextronics of
non-compliance in accordance with Section 7.1, Flextronics shall conduct or have conducted an investigation in to the manufacturing process, including analysis of any control batches of Product retained
for the purpose, and notify LumiraDx of the results of such investigations. If Flextronics is satisfied that there are manufacturing defects, it shall take account of LumiraDx’s suggestions in relation to any corrective action. LumiraDx shall,
on written instructions from Flextronics, return to Flextronics or destroy any Products rejected under this Section 7 at Flextronics’ expense. Flextronics shall then repair or replace (in line with the criteria for repair or replace set
out in Section 7.6 (f)) such Products free of charge (including any freight charge) as soon as reasonably and practicably possible. 

7.3.    If, after conclusion of the investigations set out at Section 7.2, Flextronics finds no defect in the batch
notified by LumiraDx, then either party may refer the matter for final analysis to a specialized laboratory of international reputation reasonably acceptable to both parties, subject to signing of a confidentiality undertaking by the laboratory with
a content substantially the same as Section 13.2 of this Agreement. Any determination by the laboratory shall be final and binding on LumiraDx and Flextronics. The cost of the independent laboratory shall be borne by the party whose assertion
has not been upheld by the laboratory. LumiraDx shall bear all of the risk of loss, and all costs and expenses, associated with Products that have been returned to Flextronics for which there is no defect found and shall accept such Products upon
their return to LumiraDx. 
 7.4.    The provisions of Sections 7.1-7.3 shall
survive termination or expiration of this Agreement provided that, subsequent to the termination or expiration of this Agreement, Flextronics may, in lieu of replacing any rejected or missing Products, elect to reimburse LumiraDx for such
quantities. 
 7.5.    Vendor Warranties for Materials. To the extent Flextronics receives from a vendor
of Materials or services the benefit arising from said vendor’s warranty obligations related to its Materials or services, Flextronics shall transfer such benefit to LumiraDx (without any liability for such vendor’s warranty obligations)
related to the following warranties with regard to the Materials or services: (i) conformity of the Materials or services with the vendor’s specifications and/or with the Specifications; (ii) that the Materials or services shall be
free from defects in design, materials, or workmanship; (iii) that the Materials or services shall comply with all applicable Laws; and (iv) that the Materials or services shall not infringe the intellectual property rights of third
parties. 
  

	 	7.6.	 Warranties. 

(a)    Flextronics warrants that the Products shall (i) have been manufactured in accordance with the Specifications
and, in all material respects, with applicable Laws and regulations applicable to Flextronics’s manufacture of the Products at the site of the Flextronics manufacturing facility and (ii) be free from defects in workmanship, in each case
for a period of [***] from the date of receipt at the Delivery Point. In addition, Flextronics warrants that Production Materials are in compliance with the Environmental Regulations. 

(b)    Flextronics warrants that it has obtained all corporate authorizations, and all other governmental, statutory,
regulatory or other consents, licenses and authorizations relevant to the manufacturing of the Products at the site of Flextronics manufacturing facility and required to allow it to enter into and perform the manufacturing and supply of the Products
as contemplated by this Agreement. 
 (c)    Flextronics warrants that as at the Effective Date, there is no pending or
likely governmental enforcement action or private claim against it that is reasonably expected to limit, impede or otherwise jeopardize its ability to manufacture and supply the Products as contemplated by this Agreement. 

(d)    Each party warrants that this Agreement has been duly executed by it and it constitutes legal, valid and binding
obligations which are enforceable on their terms. 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 (e)    Notwithstanding anything else in this Agreement, the warranty at
Section 7.6(a) does not apply to, and Flextronics makes no representations or warranties whatsoever (and Flextronics shall have no liability under or in connection with this Agreement) with respect to any of: (i) Materials (excluding
Production Materials to the extent expressly set forth in Section 7.6(a) or services provided by vendors on the AVL); (ii) defects resulting from adherence to the Specifications, or any instructions provided by or on behalf of LumiraDx;
(iii) the design of the Products; (iv) Product that has been abused, damaged, altered or misused or mishandled (including improper storage or installation or improper handling in accordance with static sensitive electronic device handling
requirements) by any person or entity after title passes to LumiraDx; (v) first articles, prototypes, pre-production units, test units or other similar units; (vi) defects resulting from tooling,
designs or instructions produced or supplied by LumiraDx, including any defective test equipment or test software provided by LumiraDx; or (vii) the compliance of Materials (excluding Production Materials) or Products with any safety or
Environmental Regulations or other laws. LumiraDx shall be liable for costs or expenses incurred by Flextronics arising out of or related to the foregoing exclusions to Flextronics’s express limited warranty. 

(f)    Upon any failure of a Product to comply with this express limited warranty, Flextronics’s sole obligation, and
LumiraDx’s sole remedy, is for Flextronics, at Flextronics’s option, to promptly repair (i) where such repair is capable of being provided under applicable regulatory provisions and certifications in place, technically capable of
being repaired, reasonably possible in a short period and at a cost substantially lower than a replacement option) or replace such unit and return it to LumiraDx, freight prepaid. The Parties shall discuss in good faith the choice of remedy to be
provided taken into consideration criteria outlined above, including cost calculations applicable to both Parties. In the event that such unit cannot be repaired or replaced using commercially reasonable efforts, Flextronics shall refund the price
paid by LumiraDx to Flextronics for such unit. LumiraDx shall return Products covered by this warranty freight prepaid after completing a failure report and obtaining a return material authorization number from Flextronics to be displayed on the
shipping container. This warranty will not apply to any Product that is returned more than [***] after the expiration of the warranty period set forth in Section 7.6(a). Furthermore, this warranty shall not apply if LumiraDx has removed from
Flextronics’s possession, for any reason, any tools or equipment that are necessary to repair the Product. LumiraDx shall bear all of the risk, and all costs and expenses, associated with Products that have been returned to Flextronics for
which there is no defect found. This Section sets forth Flextronics’s sole and exclusive warranty and LumiraDx’s sole and exclusive remedies with respect to a breach by Flextronics of such warranty, except in the case of responsibility for
recalls as outlined below. 
 (g)    LumiraDx shall not pass through to end users or other third parties the warranties
made by Flextronics under this Agreement. Furthermore, LumiraDx shall not make any representations to end users or other third parties on behalf of Flextronics, and (to the maximum extent permitted by law) LumiraDx shall expressly indicate that the
end users and third parties must look solely to LumiraDx in connection with any problems, warranty claim or other matters concerning the Product. 

7.7.    No Representations Conditions. Terms or Other Warranties. SAVE AS EXPRESSLY WARRANTED IN
SECTION 7.6 ABOVE, FLEXTRONICS MAKES NO REPRESENTATIONS, WARRANTIES OR CONDITIONS ON THE PERFORMANCE, QUALITY OR NATURE OF THE SERVICES, OR THE PRODUCTS, EXPRESS, IMPLIED, STATUTORY, OR IN ANY OTHER PROVISION OF THIS AGREEMENT OR COMMUNICATION
WITH LUMIRADX, AND FLEXTRONICS SPECIFICALLY DISCLAIMS ANY IMPLIED WARRANTY OR CONDITION OF MERCHANTABILITY, TITLE OR FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT. FURTHERMORE, SAVE AS EXPRESSLY
WARRANTED ABOVE AND WITHOUT PREJUDICE TO THE FOREGOING SENTENCE, ALL WARRANTIES, CONDITIONS AND OTHER TERMS IMPLIED BY STATUTE (INCLUDING, WITHOUT LIMITATION, SECTIONS 13-15 OF THE SALE OF GOODS ACT 1979 AND
SECTIONS 3-5 AND 13 OF THE SUPPLY OF GOODS AND SERVICES ACT 1982), COMMON LAW, CUSTOM OF THE TRADE, COURSE OF DEALING OR OTHERWISE ARE EXCLUDED TO THE FULLEST EXTENT PERMITTED BY LAW. 

 

	8.	 REGULATORY COMPLIANCE, RECALLS 

8.1.    Regulatory Approvals, LumiraDx shall be responsible for applying for, obtaining, and maintaining at
its cost and expense any regulatory and agency approvals required for the development, marketing or sale of the Products in the countries where Products may be sold, used or destined. 

8.2.    Flextronics shall obtain and maintain for the term of this Agreement all licenses, permissions, authorizations,
consents and permits needed for manufacturing of the Products at Flextronics manufacturing facility in accordance with the 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 
terms of this Agreement. Flextronics shall, in particular, be responsible for its registration with the FDA as a contract manufacturer handling finished devices. Flextronics shall also host any
notified body, or other relevant regulatory body and certification body audits for LumiraDx relating to its manufacturing practices to enable LumiraDx to comply with its regulatory requirements. 

 

	 	8.3.	 Disbarred Persons 

Flextronics shall use its best endeavors to ensure that none of its Representatives are disbarred persons under FDA regulations and that they
do not become disbarred under the FDA regulations. Flextronics shall notify LumiraDx should it become aware of any circumstances in which one of its (or its Affiliates) employees may become disbarred under FDA regulations. 

8.4.    Product Complaints/ Reports. Flextronics shall notify LumiraDx promptly after receiving any
complaint or return and provide LumiraDx with a complete copy of the complaint and all other relevant information and shall provide reasonable assistance to LumiraDx in resolving or addressing any such complaint. 

8.5.    LumiraDx shall be responsible for handling all complaints and inquiries related to the Products made by users of
the Products, and any reporting requirements related thereto. Flextronics shall: (i) inform LumiraDx immediately of any complaints received by it relating to the Products, (ii) assist LumiraDx with any investigation of any device that has
experienced a failure in accordance with Section 7.1 and (iii) undertake any corrective actions as soon as reasonably possible with a target of [***] to implement corrective action in the manufacturing process. Should Flextronics become
aware of any potential or actual information relating to a device which may lead to a complaint or inquiry being made, it shall inform LumiraDx within [***], and perform any investigations and applicable corrective actions in compliance with
Sections 7.2 and 7.3 within [***] at its own expense. 
 8.6.    Recalls. If either Party believes that a
recall, market withdrawal, safety alert or similar corrective action (“Recall”) of the Products may be desirable or required by applicable Laws or by any relevant regulation body, it shall immediately notify the other Party
in writing. If a Recall is necessary or deemed advisable by LumiraDx, each party shall promptly provide reasonable cooperation to the other in recalling the Product. LumiraDx shall be responsible for all Recalls and other corrective actions
associated with Products. Flextronics shall promptly reimburse LumiraDx, up to the liability cap specified in Section 12.3 (B) for all documented transportation and storage expenses that LumiraDx incurs in connection with the Recall of a
defective Product, where LumiraDx can demonstrate that the relevant defective Product was subject to Flextronics· warranty set out in Section 7.6 (a). 

8.7.    Flextronics will not act to initiate a Recall without the express prior written approval of LumiraDx. In the case
of a Recall all other claims and remedies, including all claims for damages, in connection with the Recall shall be excluded unless the claim is based on willful intent or a deliberate default. 

 

	9.	 TERM AND TERMINATION 

9.1.    Term. Subject to termination as expressly set forth in this Agreement, (a) the term of this
Agreement shall commence on the Effective Date and shall continue for two years thereafter, and (b) after the expiration of the initial term hereunder, this Agreement shall be automatically renewed for separate but successive [***] terms unless
either party provides written notice to the other party that it does not intend to renew this Agreement [***] or more prior to the end of any term. 

9.2.    Termination. This Agreement may be terminated by either party (a) for convenience upon [***]
written notice to the other party, subject to the provisions of Section 9.1 above, (b) if the other party defaults in any payment to the terminating party and such default continues without a cure for a period of [***] after the delivery
of written notice thereof by the terminating party to the other party, (c) if an Insolvency Event occurs in relation to the other party or (d) if the other party materially defaults in the performance of any other term or condition of this
Agreement (other than payment) and such default continues un-remedied for a period of [***] after the delivery of written notice thereof by the terminating party to the other party of its intention to exercise
its rights under this Section, or (d) in accordance with the provision addressing Force Majeure events. 

9.3.    Effect of Expiration or Termination. Expiration or termination of this Agreement under any of the
foregoing provisions: (a) shall not affect the amounts due under this Agreement by either party that exist as of the date of 

  
 - 10 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 
expiration or termination (or any other accrued rights or obligations prior to the termination date), (b) as of such date the provisions of Section 6 shall apply with respect to payment and
shipment to LumiraDx of all Inventory in existence as of such date and (c) the license granted under Section 13.3 shall terminate with immediate effect. The following Sections, and any terms or provisions necessary to interpret or enforce
such Sections, shall survive any termination or expiration of this Agreement: 1, 3.6, 3.7, 5, 7, 9, 10, 12, 13.1, 13.4, 13.11, 13.14, 13.15, 13.17 and 13.18. 

In the case of termination of this Agreement for whatever reason, all claims for damages and all other claims in connection with the non-continuation of this Agreement shall be excluded unless the claim is based on willful intent or a deliberate default. 

10. INDEMNIFICATION; LIABILITY LIMITATION 

10.1.    Indemnification by Flextronics. Flextronics agrees to defend, indemnify and hold harmless, LumiraDx
and each of its Representatives (each, a “LumiraDx lndemnitee”) from and against all claims, actions, losses, expenses, damages or other liabilities, including reasonable attorneys’ fees (collectively,
“Damages”) incurred by or assessed against any LumiraDx Indemnitee claims relating to, but solely to the extent arising out of third-party claims regarding: 

(a)    any actual or alleged injury or damage to any person (including death) or property caused, or alleged to be caused,
by a Product sold by Flextronics to LumiraDx hereunder, including third-party product liability claims based on breach of products liability legislation, but solely to the extent such injury or damage has been caused by the breach by Flextronics of
its warranties set forth in Section 7.6; 
 (b)    any actual or alleged infringement or misappropriation of the
intellectual property rights (including any industrial design rights, database rights or any other form of intangible or business property rights) of any third party, but solely to the extent that such infringement or misappropriation is caused by a
process or Production Materials that Flextronics elects to use to manufacture, assemble or test the Products; however, Flextronics shall not have any obligation to indemnify LumiraDx if such claim would not have arisen but for Flextronics’s
manufacture, assembly or test of the Product in accordance with the Specifications; 
 (c)    noncompliance with any
Environmental Regulations but solely to the extent that such non-compliance is caused by a process or Production Materials that Flextronics uses to manufacture the Products; provided that, Flextronics shall
not have any obligation to indemnify Customer if such claim would not have arisen but for Flextronics’s manufacture of the Product in accordance with the Specifications. 

10.2.    Indemnification by LumiraDx. LumiraDx agrees to defend, indemnify and hold harmless, Flextronics
and each of its Representatives (each, a “Flextronics lndemnitee”) from and against all Damages incurred by or assessed against any Flextronics lndemnitee, but solely to the extent arising out of third-party claims relating to the
Products, except to the extent that Flextronics indemnifies LumiraDx pursuant to Section 10.1. 

10.3.    Procedures for Indemnification. If a party (the “Claiming Party”) becomes aware of
any claim or potential claim by a third party (a “Third Party Claim”), or of any other matter or circumstance, which may result in a claim being made against it and for which it would be indemnified under this Agreement by the other
party (the “Indemnifying Party”), the Claiming Party shall: 
 (a)    promptly, and in any event
within [***] of it becoming aware of it, give notice of the Third Party Claim to the Indemnifying Party and ensure that the Indemnifying Party is given all reasonable information and facilities to investigate it; 

(b)    not (and ensure that its Affiliates do not) admit liability or make any agreement or compromise in relation to the
Third Party Claim without prior written approval of the Indemnifying Party; 
 (c)    have the right to participate in
the defense of the Third Party Claim and to employ counsel, at its own expense, separate from the counsel employed by the Indemnifying Party, or 

(d)    subject to the Claiming Party being indemnified by the Indemnifying Party against all reasonable out of pockets
costs and expenses incurred in respect of that Third Party Claim upon the admission of the Indemnifying Party that such 

  
 - 11 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 
claim is its responsibility, or upon the determination by a judge or arbiter that the Indemnifying Party was responsible for the defense of that Third Party Claim, ensure that the Claiming Party
and each of its Affiliates shall: 
 (i)    take such action as the Indemnifying Party may reasonably
request to avoid, resist, dispute, appeal, compromise or defend the Third Party Claim; 
 (ii)    allow
the Indemnifying Party (if it elects to do so) to take over conduct of all proceedings and/or negotiations arising in connection with the preparation for and conduct of any proceedings and/ or negotiations relating to the Third Party Claim. 

10.4.    Sale of Products Enjoined. Should the use of any Products be enjoined, or in the event the
Indemnifying Party desires to minimize its liabilities under this Section, then in addition to its indemnification obligations set forth in this Section, the Indemnifying Party may either substitute a fully equivalent Product or process not subject
to such injunction or possible liability, modify such Product or process so that it no longer is subject to such injunction or possible liability, or obtain the right to continue using the Product or process in question. In the event that any of the
foregoing remedies cannot be effected on commercially reasonable terms, then all accepted purchase orders and the current Forecast shall be considered cancelled and LumiraDx shall purchase all Products and partially completed Products which
Flextronics is not enjoined from selling, [Inventory and Special Inventory] as provided in this Agreement. Any changes to any Products or process must be made in accordance with this Agreement. Notwithstanding the foregoing, in the event that a
third party files an infringement complaint but does not obtain an injunction, the Indemnifying Party shall not be required to substitute a fully equivalent Product or process or modify the Product or process if the Indemnifying Party obtains an
opinion from competent patent counsel reasonably acceptable to the other party or otherwise provides reasonable assurances that such Product or process is not infringing or that the patents alleged to have been infringed are invalid. 

11. QUALITY AGREEMENT 

11.1.    Subject to applicable Laws, the parties shall enter into the Quality Agreement, as of the Effective Date, and
comply with the requirements and provisions set out therein. The Quality Agreement is annexed to this Agreement as Exhibit 2. 
 12. LIMITATIONS OF
LIABILITY 
 12.1.    Bargained-For Exchange. The parties agree
that the limitations and exclusive remedies set forth in this Agreement are reasonable and represent the negotiated allocations of risk between the parties and are reflective of the pricing and bargained-for
exchange represented herein. Other than as expressly set forth in this Agreement, and subject to the terms and conditions of this Agreement, including the limitations set forth below, the parties acknowledge that LumiraDx has not relied on any
representations by Flextronics with respect to the Products or Flextronics’s performance. 

12.2.    Exclusions of Certain Forms of Damages. EXCEPT WITH RESPECT TO A PARTY’S OBLIGATIONS OF
INDEMNIFICATION AS SET FORTH IN THIS AGREEMENT OR A BREACH OF A PARTY’S OBLIGATIONS OF CONFIDENTIALITY HEREUNDER, IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER (OR ITS AFFILIATES) (1) FOR ANY INCIDENTAL, CONSEQUENTIAL,
SPECIAL OR PUNITIVE DAMAGES OF ANY KIND OR NATURE ARISING OUT OF OR RELATING TO THIS AGREEMENT, PERFORMANCE OF ANY SERVICES OR THE SALE OF PRODUCTS, OR (2) FOR ANY LOSS OF USE, DATA, BUSINESS, OPPORTUNITY OR PROFITS, LOST REVENUES OR DAMAGES
RESULTING FROM VALUE ADDED TO THE PRODUCT BY LUMIRADX (IN EACH CASE WHETHER DIRECTLY OR INDIRECTLY ARISING), WHETHER ANY SUCH LIABILITY IS ASSERTED ON THE BASIS OF CONTRACT, TORT (INCLUDING WITHOUT LIMITATION THE POSSIBILITY OF NEGLIGENCE OR STRICT
LIABILITY), OR OTHERWISE (EXCEPT IN EITHER CASE WHERE THE GOOD WILL OF A PARTY IS DAMAGED BY A DELIBERATE DEFAULT OF THE OTHER PARTY). 

12.3.     Limitations on Liability. 

(A) WITH THE EXCEPTION OF BREACHES OF SECTIONS 7, 8.6, 10, OR 13.1-13.3, AND TO THE MAXIMUM EXTENT
PERMITTED BY LAW, TERMINATION OF THIS AGREEMENT AND THE SETTLING OF ACCOUNTS IN THE MANNER SET FORTH IN SECTION 9.3 SHALL BE THE EXCLUSIVE REMEDY OF THE PARTIES FOR BREACH OF THIS AGREEMENT. 

(8) EXCEPT WITH RESPECT TO (i) FLEXTRONICS’S OBLIGATIONS OF INDEMNIFICATION AS SET FORTH IN THIS AGREEMENT OR (ii) A BREACH OF
FLEXTRONICS’S OBLIGATIONS OF CONFIDENTIALITY HEREUNDER OR (iii) SAVE IN RESPECT TO LIABILITY WHICH MAY NOT BE LIMITED UNDER APPLICABLE LAW, THEN NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, FLEXTRONICS’S TOTAL LIABILITY
TO 

  
 - 12 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 
LUMIRADX (TOGETHER WITH ALL LUMIRADX AFFILIATES) HEREUNDER SHALL BE SUBJECT TO AN AGGREGATE CAP IN ACCORDANCE WITH THE FOLLOWING: THE TOTAL, AGGREGATE AND CUMULATIVE LIABILITY OF FLEXTRONICS, IF
ANY, FOR DAMAGES FOR ALL CLAIMS UNDER THIS AGREEMENT OF ANY KIND WHATSOEVER, REGARDLESS OF LEGAL THEORY (WHETHER BREACH OF CONTRACT, NEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE), SHALL NOT EXCEED AT ANY GIVEN TIME AN AMOUNT DETERMINED AS
FOLLOWS: [***] OF THE TOTAL AMOUNTS RECEIVED BY FLEXTRONICS FROM LUMIRADX ON ACCOUNT OF THE SALE OF PRODUCTS HEREUNDER IN THE IMMEDIATELY PRECEDING TWELVE MONTHS LESS ANY CLAIM($) PREVIOUSLY PAID BY FLEXTRONICS TO LUMIRADX AT ANY TIME DURING THE
TERM OF THIS AGREEMENT. 
 12.4.     No limitation. 

 

	 	(A)	 NOTHING IN THIS AGREEMENT SHALL LIMIT OR EXCLUDE EITHER PARTY’S LIABILITY TO THE OTHER PARTY (OR ANY OF
ITS AFFILIATES) FOR: 

  

	 	(I)	 FRAUD OR FRAUDULENT MISREPRESENTATION OR A DELIBERATE DEFAULT; 

 

	 	(II)	 ANY OBLIGATION HEREUNDER TO INDEMNIFY THE OTHER PARTY; OR, 

 

	 	(Ill)	 ANY LIABILITY WHICH MAY NOT BE EXCLUDED OR LIMITED UNDER APPLICABLE LAW. 

 

	 	(8)	 NOTHING IN THIS AGREEMENT SHALL LIMIT OR EXCLUDE LIABILITY FOR: 

 

	 	(I)	 LUMIRADX’S OBLIGATION HEREUNDER FOR PAYMENTS FOR PRODUCT, MATERIALS OR OTHER CHARGES; OR

  

	 	(II)	 FLEXTRONICS’S WARRANTY OBLIGATIONS HEREUNDER AS SET OUT IN SECTION 7.6. 

13. MISCELLANEOUS 

13.1.    Confidentiality. Each party shall keep confidential and not use anv Confidential Information of the
disclosing party for any purposes or activities other than in support of such party’s obligations established in this Agreement. Except as otherwise specifically permitted herein or pursuant to written permission of the disclosing party,
neither party shall disclose or facilitate disclosure of Confidential Information of the disclosing party to any third party, except that the receiving party may disclose such Confidential Information to (i) those of its Affiliates and their
respective employees, consultants, and other agents who need to know such Confidential Information for carrying out the activities contemplated by this Agreement and/or (ii) third party suppliers or vendors for the purpose of obtaining price
quotations; provided, however, that in either case, the recipient has agreed in writing to confidentiality terms that are no less restrictive than the requirements of this Section. Notwithstanding the foregoing, the receiving party may disclose
Confidential Information of the disclosing party pursuant to a required court order, subpoena other governmentally-required process or as required by the rules of any applicable stock exchange; however, in such circumstance, the receiving party
shall, to the extent reasonably feasible and permissible: (a) give the disclosing party prompt notice of the receiving party’s receipt or knowledge of such required disclosure; and (b) provide the disclosing party a reasonable
opportunity to oppose such process or to obtain a protective order at the disclosing party’s expense. Subject to each party’s right to maintain copies of Confidential Information in accordance with such party’s reasonable
record-keeping requirements, Confidential Information of the disclosing party in the custody or control of the receiving party shall be promptly returned, destroyed or expunged from any computer, word processor or other device upon the earlier of
(i) the disclosing party’s written request, or (ii) termination of this Agreement, unless such information must be maintained in accordance with applicable Laws or the rules of any relevant regulatory authority or applicable stock
exchange. Confidential Information disclosed pursuant to this Agreement shall be maintained confidential for a period of three (3) years after the disclosure thereof. The existence and terms of this Agreement are Confidential Information of
Flextronics. 
 13.2.    Use of Flextronics or LumiraDx Name is Prohibited. Neither party may use the
other party’s name or identity or any other Confidential Information in any advertising, promotion or other public announcement, press release or statement without the prior express written consent of the other party. 

13.3.    Use of LumiraDx Intellectual Property Rights. In the event that Flextronics requires any legal
right, or the use of any asset, controlled by LumiraDx to carry out the arrangements contemplated under this Agreement, LumiraDx hereby grants Flextronics a limited license to said legal right or asset to the extent necessary to carry out its
obligations under this Agreement. 

  
 - 13 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 13.4.    Construction: Entire Agreement: The terms and
conditions as set forth in this Agreement have been arrived at after mutual negotiation, and it is the intention of the parties that its terms and conditions not be construed against any party merely because the Agreement was prepared by one of the
parties. Subject to the terms of this Agreement, this Agreement, all Exhibits and attachments hereto and all Specifications constitute the entire agreement between the parties with respect to the transactions contemplated hereby and supersede all
prior agreements and understandings between the parties relating to such transactions. Each party waives all claims, rights and remedies for all representations: (a) made to it by any person before entering into this Agreement; and (b) not
set out in this Agreement. Each party acknowledges, in deciding to enter into this Agreement and each purchase order, it has not relied on any such representation. This clause does not exclude or restrict liability for fraud. If the scope of any of
the provisions (or any portion of a provision) of this Agreement is too broad to permit enforcement to its full extent, then such provisions shall be enforced to the maximum extent permitted by law, and the parties agree that such scope may be
judicially modified accordingly and that the whole of such provisions of this Agreement shall not thereby fail, but that the scope of such provisions shall be curtailed only to the extent necessary to conform to the law. The Quality Agreement shall
be subject to the terms and condition of this Agreement. In the event of any conflict between the Quality Agreement and this Agreement, this Agreement shall prevail. 

13.5.    Severance. Each provision of this Agreement is severable and distinct from the others and, if any
provision is, or at any time becomes, to any extent or in any circumstances invalid, illegal or unenforceable for any reason, that provision shall to that extent be deemed not to form part of this Agreement but the validity, legality and
enforceability of the remaining provisions of this Agreement shall not be affected or impaired, it being the parties’ intention that every provision of this Agreement shall be and remain valid and enforceable to the fullest extent permitted by
law. 
 13.6.    Amendments: Waiver. This Agreement may be amended only by written consent of both
parties. The failure by either party to enforce any provision of this Agreement shall not constitute a waiver of future enforcement of that or any other provision. 

13.7.    Independent Contractor. Nothing in this Agreement is deemed to constitute a partnership between the
parties and nothing contained in this Agreement shall constitute the parties as joint venture partners, co-owners, employer and employee or otherwise as participants in a joint or common undertaking. Neither
party shall, for any purpose, be deemed to be an agent of the other party, and the relationship between the parties shall only be that of independent contractors. Neither party shall have any right or authority to assume or create any obligations or
to make any representations or warranties on behalf of any other party, whether express or implied, or to bind the other party in any respect whatsoever. 

13.8.    Insurance. Each party agrees to maintain appropriate insurance to cover such party’s
respective risks and liabilities under this Agreement with coverage amounts commensurate with such risks and liabilities, taking into account each party’s capability for self-insurance. 

13.9.    Force Majeure. In the event that either party is prevented from performing or is unable to perform
any of its obligations under this Agreement (other than a payment obligation) due to any act of God, acts or decrees of governmental or military bodies, fire, casualty, flood, earthquake, war, strike, lockout, epidemic, destruction of production
facilities, riot, insurrection, Materials unavailability, the failure of equipment or tooling provided by LumiraDx except to the extent such failure was caused by Flextronics, or any other cause beyond the reasonable control of the party invoking
this Section (collectively, a “Force Majeure”), and if such party shall have used its commercially reasonable efforts to mitigate its effects, such party shall give prompt written notice to the other party, its performance
shall be excused, and the time for the performance shall be extended for the period of delay or inability to perform due to such occurrences. Regardless of the excuse of Force Majeure, if such party is not able to perform within [***] after such
event, the other party may terminate the Agreement. 
 13.10.    Successors. Assignment. This Agreement
shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns and legal representatives. Neither party shall have the right to assign or otherwise transfer its rights or obligations under this
Agreement except with the prior written consent of the other party, not to be unreasonably withheld. Subject to the provisions of this Agreement, Flextronics may subcontract, delegate, novate or assign some or all of its rights and obligations under
this Agreement to an Affiliate of Flextronics or to a third party financial institution for the purpose of receivables financing (e.g., factoring). LumiraDx may subcontract, delegate, novate or assign

  
 - 14 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

 
some or all of its rights and obligations under this Agreement to an Affiliate of LumiraDx with prior written consent of Flextronics, which consent not to be withheld unreasonably. LumiraDx shall
remain fully responsible and liable for its assignees, subcontractors and delegates performance in accordance with the terms and conditions of this Agreement. 

13.11.     Notices. A notice or other communication given under or in connection with this Agreement
must be: 
 (a) in writing; 

(b) in the English language; and 

(c) sent by a Permitted Method to the Notified Address. 

13.12.    The Permitted Method means any of the methods set out in column (1) below. A notice given by the Permitted
Method will be deemed to be given and received on the date set out in column (2) below. 
  

			
	 (1)

Permitted Method
	  	 (2)

Date on which notice deemed given and

received

	Personal delivery	  	If left at the Notified Address before 5pm on a Business Day, when left and otherwise on the next Business Day
		
	Ordinary first class pre-paid post or prepaid recorded or special delivery, where the Notified Address is in the same country as that from which the notice is sent	  	1 Business Days after posting
		
	Ordinary pre-paid airmail or prepaid recorded or special delivery (or the nearest local equivalent in the jurisdiction of the sender), where the Notified Address is in one country and the
notice is sent from another	  	1 Business Days after posting
		
	Commercial overnight courier	  	2 Business Days after depositing

 13.13.     The Notified Address of each of the parties is as set out below: 

 

					
	 Name of

party      
	  	 Address
	  	 Marked for the attention

of:                
                      

	LumiraDx	  	 3 More Riverside London,
 London, SE1 2AQ,
UK
	  	General Counsel
			
	Flextronics	  	 Flextronics Medical Sales and Marketing, Ltd

[***]
 [***]
	  	General Counsel

  
 - 15 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

					
	 Name of

party     
	  	 Address
	  	 Marked for the attention

of:                
                      

		  	 [***]
  

With a copy sent to:
  

Flextronics International USA, Inc.
 [***]

[***]
	  	

 or such other Notified Address as either party may, by notice to the other, substitute for their Notified
Address set out above. 
 13.14.     Service of Process 

Flextronics hereby irrevocably authorizes and appoints Flextronics Medical Sales and Marketing, Ltd, [***] to accept on its behalf service of
all legal process arising out of or in connection with any dispute resolution process in connection with this Agreement. Flextronics agrees that: 

(a)    failure by Flextronics Medical Sales and Marketing, Ltd to notify it of the process will not invalidate the dispute
resolution process concerned; and 
 (b)    if this appointment is terminated for any reason whatsoever, it will appoint
a replacement agent having an office or place of business in England or Wales and will notify LumiraDx of this appointment. 

13.15.     Disputes Resolution. 

(a)     This Agreement and its interpretation (and all non-contractual obligations
arising from or connected with this Agreement) shall be governed by and interpreted in accordance with the laws of England and Wales without regard to its conflicts of laws provisions. The parties specifically agree that the 1980 United Nations
Convention on Contracts for the International Sale of Goods, as may be amended from time to time, shall not apply to this Agreement. 

Arbitration 

(b)     If the parties fail to resolve the Dispute [***] and a party desires to pursue resolution of the Dispute, the
Dispute shall be submitted by either party for resolution in arbitration under the London Court of International Arbitration Rules from time to time in force. This Section incorporates the Rules except where they conflict with its express terms. The
number of arbitrators shall be three. The seat, or legal place, of arbitration shall be London, England. The language to be used in the arbitral proceedings shall be English. 

Each party shall nominate an arbitrator in the Request for Arbitration or Answer as the case may be. The two party nominated arbitrators shall nominate a
third arbitrator to act as Chairman within [***] after confirmation of the second arbitrator’s appointment. If any of the parties fail to nominate an arbitrator or the two arbitrators already appointed fail to nominate the Chairman, the
appointments shall be made by the LCIA Court. The award shall be final and binding on the parties or anyone claiming through or under them and judgment rendered on the award may be entered in any court having jurisdiction or application may be made
to such court for judicial acceptance of the award and an order of enforcement as the case may be. 

  
 - 16 - 

 

         FLEXTRONICS CONFIDENTIAL 
  

 (c)    IN THE EVENT OF ANY DISPUTE BETWEEN THE PARTIES, WHETHER IT
RESULTS IN PROCEEDINGS IN ANY COURT IN ANY JURISDICTION OR IN ARBITRATION, THE PARTIES HEREBY KNOWINGLY AND VOLUNTARILY, AND HAVING HAD AN OPPORTUNITY TO CONSULT WITH COUNSEL, WAIVE ALL RIGHTS TO TRIAL BY JURY, AND AGREE THAT ANY AND ALL MATTERS
SHALL BE DECIDED BY AN ARBITRATOR WITHOUT A JURY TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW. To the extent applicable, in the event of any lawsuit between the parties arising out of or related lo this Agreement, the parties agree to
prepare and to timely file in the applicable court a mutual consent to waive any statutory or other requirements for a trial by jury. 

13.16.    Further Documents. Each party shall execute or procure the execution of any further documents as may be
required by applicable Laws or be necessary to implement and give effect to this Agreement. 
 13.17.    Record
Keeping. Flextronics shall maintain in accordance with generally accepted accounting principles, complete and accurate records relating to the manufacture of the Products as required by applicable Laws. Flextronics shall maintain such records
during the relevant retention period required by applicable Laws. 
 13.18.    Audits. LumiraDx or its
Representatives (or anyone authorized by LumiraDx, including any relevant regulatory authority) may audit such records of Flextronics at any time during the term of this Agreement and or the retention period under Section 13.17. Flextronics
shall make such records readily available for such an audit. Unless otherwise agreed in writing, LumiraDx or its Representatives (or anyone authorized by LumiraDx including any relevant regulatory authority) shall not make copies of any records.

 13.19.    Third Party Rights. A person who is not a party to this Agreement has no right under the Contracts
(Rights of Third Parties) Act 1999 to enforce any of its terms. The parties agree that certain provisions of this Agreement confer a benefit on their respective Affiliates, and that such provisions are intended to benefit, and be enforceable by,
such Affiliates In their own right under the Contracts (Rights of Third Parties) Act 1999. Notwithstanding the foregoing, under no circumstances shall any consent be required from any such Affiliate for the termination, rescission, amendment or
variation of this Agreement, whether or not such termination, rescission, amendment or variation affects or extinguishes any such benefit or right. 

13.20.    Waivers, rights and remedies. The rights and remedies of each party to this Agreement are, except
where expressly stated to the contrary, without prejudice to any other rights and remedies available to ii. No neglect, delay or indulgence by either party in enforcing any provision of this Agreement shall be construed as a waiver and no single or
partial exercise of any rights or remedy of either party under this Agreement will affect or restrict the further exercise or enforcement of any such right or remedy. 

13.21.     Controlling Language. This Agreement is in English only which language shall be controlling in all
respects. All documents exchanged under this Agreement shall be in English. 
 13.22.    Counterparts and Exchange of
Signatures. This Agreement may be executed in counterparts. The parties agree that electronically transmitted and reproduced signatures (including faxed pages, scanned copies of signatures and email acknowledgements) constitute acceptable
exchange of authentic consent to the terms and conditions of this Agreement. 
 IN WITNESS WHEREOF, the parties have caused this Manufacturing Services
Agreement to be duly executed by their duly authorized representatives as of the Effective Date. 
  

									
	LUMIRADX UK LIMITED:	 		 	FLEXTRONICS MEDICAL SALES AND MARKETING, LTD.: 

									
					
	Signed:	 	 /s/ David
Scott                    
	 		 	Signed:	 	 /s/ Manny
Marimuthu                        

	Print Name:	 	David Scott	 		 	Print Name:	 	Manny Marimuthu                                
	Title:	 	Director	 		 	Title:	 	Director                            

 

         FLEXTRONICS CONFIDENTIAL 
  

 Exhibit 1 

Definitions 
 Unless defined elsewhere in
this Agreement, the following terms have the following meanings: 
  

			
	“Adequate Procedures”	  	means policies, procedures, processes and systems designed to ensure, and which are reasonably expected to continue to ensure, compliance with the applicable Anti-Bribery Laws, including the adequate procedures referred to in
section 7(2) of the Bribery Act 2010 and the guidance issued by the Ministry of Justice pursuant to section 9 of the Bribery Act 2010 designed to prevent the relevant organisation’s Representatives and Associated Persons from bribing another
person for the purposes of section 7(3) of the Bribery Act 2010
		
	“Affiliate”	  	means any corporation, partnership, joint venture or other legal entity that a party to this Agreement controls, is under common control with, or is controlled by, where “control” means the ownership of more than fifty
percent (50%) of the voting equity in such entity or otherwise the ability to direct the management of such entity.
		
	“Aged Inventory”	  	means either of any Product, partially completed Product, Inventory or Special Inventory, or some or all, for which there has been zero or insignificant consumption over the past [***], which includes any particular item that
Flextronics has had on hand for more than [***].
		
	“Anti-Bribery Laws”	  	means the UK Bribery Act 2010, the U.S. Foreign Corrupt Practices Act of 1977, the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions 1997 and the UN Convention Against
Corruption 2003 (save to the extent such conventions conflict with applicable law) (in each case as amended from time to time) and any applicable law, rule, regulation and other legally binding measure relating to the prevention of bribery,
corruption, fraud or similar or related activities of all countries to which either party or their Affiliates are subject
		
	“Approved Vendor List” or “AVL”	  	means the list of vendors approved to provide the Materials or services specified in the bill of materials for a Product.
		
	“Associated Person”	  	means in relation to an organisation, a person (including an employee, agent or subsidiary) who performs or has performed services (including within the meaning of section 8 of the Bribery Act 2010) for that organisation or on
its behalf and in respect of whose actions or inactions the organisation may be liable under Anti-Bribery Laws
		
	“Business Day”	  	means any day of the week (excluding Saturday and Sunday) on which commercial banks are open for business in England and Mauritius
		
	“cGMP”	  	means current good manufacturing practices, all applicable Laws and quality standards as set out in the Quality Agreement applied at the site of manufacture and control as amended from time to time

  
 - 18 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

			
	“Compliance Requirements”	  	means all applicable Law relevant to the manufacturing of the Products at the site of Flextronics manufacturing facility, the terms of this Agreement, the terms of the Quality Agreement and cGMP
		
	“Confidential Information”	  	means (a) the existence and terms of this Agreement except that the existence of this Agreement may be disclosed for purposes of enforcing the Agreement pursuant to Section 11.10, (b) all information concerning the fees
or costs for Products and Inventory other than LumiraDx Controlled Materials, (c) any know how relating to the manufacture of the Products or the Materials and (d) any other information that is marked “Confidential” or the like
or, if delivered verbally, confirmed in writing to be “Confidential” within [***] of the initial disclosure. Confidential Information does not include information that (i) the receiving party can prove it already knew at the time of
receipt from the disclosing party free of any obligations of confidentiality; (ii) has come into the public domain without breach of confidence by the receiving party; (iii) was received from a third party without restrictions on its use;
(iv) the receiving party can prove it independently developed without use of or reference to the disclosing party’s data or information; or (v) the disclosing party agrees in writing is free of such restrictions.
		
	“Dispute”	  	means any dispute arising out of or in connection with this Agreement or as to its interpretation
		
	“FDA”	  	means the US Food and Drug Administration (or any successor body).
		
	“Economic Order Inventory”	  	means Materials purchased in quantities above the required amount for purchase orders and the Forecast in order to achieve price targets for such Materials.
		
	“Environmental Regulations”	  	means any applicable hazardous substance content laws and regulations including, without limitation, those related to or implementing EU Directive 2011/65/EU about the Restriction of Use of Hazardous Substances (RoHS) and (EC
1907/2006) dealing with the registration, evaluation, authorization and restriction of chemical substances (REACH).
		
	“Excess Inventory”	  	means either of any Product, partially completed Product, Inventory or Special Inventory, or some or both, owned by Flextronics that is not required for consumption to satisfy the next [***] of demand for Products under the then
current purchase order(s) and Forecast.
		
	“Governmental Change”	  	has the meaning set forth in Section 3.4(b).
		
	“Insolvency Event”	  	means where one party becomes insolvent or is generally unable to pay, or fails to pay, its debts when they become due or files (or has filed against it) a petition for voluntary or involuntary bankruptcy or otherwise becomes
subject to any proceeding under any domestic or foreign bankruptcy or insolvency law, makes or seeks to make a general assignment for the benefit of its creditors, or applies for or has appointed a receiver, trustee, custodian or similar agent
appointed by order of any court of competent jurisdiction to take charge or sell any material portion of its property or business.
		
	“Inventory”	  	means any Materials that are procured by or on-order with Flextronics in accordance with the applicable Lead Time for use in the manufacture of Products pursuant to a purchase order or
Forecast from LumiraDx.
		
	“Laws”	  	include any federal, state, foreign or local law, common law, statute, ordinance, rule, registration, code or order promulgated or issued by any governmental authority in any relevant jurisdiction.

  
 - 19 - 

 

         FLEXTRONICS CONFIDENTIAL 
  

			
	“Lead Time”	  	means the Materials Procurement Lead Time plus the manufacturing cycle time required from the delivery of the Materials at Flextronics’s facility to the completion of the manufacture, assembly and test processes.
		
	“Lumira Dx Limited”	  	means Lumira Dx Limited whose registered office is at 3 More London Riverside, London, SE1 2AQ, the parent company of the Lumira Group (or such other company which may be the parent company of the Lumira Group from time to
time).
		
	“Lumira Group”	  	means Lumira Dx Limited and its subsidiaries from time to time
		
	“LumiraDx Controlled Materials”	  	means those Materials provided by LumiraDx or by vendors with whom LumiraDx has a commercial relationship.
		
	“LumiraDx Controlled Materials Terms”	  	means the terms and conditions that govern the purchase of LumiraDx Controlled Materials.
		
	“Material Overhead Costs” or “MOH”	  	means Flextronics’s fee for acquiring, managing and storing Materials, which may be expressed as a percentage of the Standard Cost of the Materials, as such percentage is set forth in the applicable bill of materials or
other document; if no MOH is specified in the applicable documents, then the MOH shall be equal to: [***].
		
	“Materials”	  	means components, parts, raw material and subassemblies that comprise the Product and that appear on the bill of materials for the Product.
		
	“Materials Procurement Lead Time”	  	means, with respect to any particular item of Materials, the longer of (a) [***] time to obtain such Materials as recorded on Flextronics’s system of record or (b) the actual lead time.
		
	“Minimum Order Inventory”	  	means Materials purchased in excess of requirements for purchase orders and Forecast because of minimum lot sizes required by the vendor.
		
	“Monthly Charges”	  	means a monthly finance carrying charge of [***], and storage and handling charge of [***].
		
	“NRE Charges”	  	means Product-specific tooling, equipment or software and other reasonably necessary non-recurring set-up, tooling or similar expenses as set forth
in Flextronics’s pricing quotations.
		
	“Obsolete Inventory”	  	means either of any Product, partially completed Product, Inventory or Special Inventory, or some or all, that is any of the following: (a) removed from the bill of materials for a Product by an engineering change;
(b) no longer on an active bill of materials for any of LumiraDx’s Products; or (c) on-hand with Flextronics but not required for consumption to satisfy the next [***] of demand for Products
under the then-current purchase order(s) and Forecast.
		
	“Products”	  	means an item in its completed form as described in written and agreed upon Specifications and that is the object of the Services.
		
	“Production Materials”	  	means materials that are consumed in the production processes to manufacture Products including without limitation, solder, epoxy, cleaner solvent, labels, flux, and glue; Production Materials do not include any such production
materials that have been specified by the LumiraDx or any LumiraDx Controlled Materials.
		
	“Quality Agreement”	  	shall mean the quality agreement mutually agreed to by the parties, which is incorporated herein by reference and attached as Exhibit 2 hereto.

  
 - 20 - 

			
	 

  
	 	FLEXTRONICS CONFIDENTIAL

  

			
	“Representatives”	  	means, in relation to a party, the directors, officers, employees, agents, advisers, accountants and consultants of that party and/ or its respective Affiliates
		
	“Services”	  	has the meaning set forth in Section 2.1(a).
		
	“Special Inventory”	  	means any Minimum Order Inventory, Economic Order Inventory, safety stock and other mutually-agreed Inventory acquired by Flextronics in excess of the Forecast to support flexibility or demand requirements.
		
	“Specifications”	  	means the agreed detailed instructions provided by LumiraDx (prior to the commencement of manufacturing of the Products by Flextronics) (as amended from time to time), defining each Product, which shall include, without
limitation: bills of materials, designs, schematics, assembly drawings, process documentation, test specifications, current revision number, and an Approved . Vendor List
		
	“Standard Cost”	  	means, as applicable, (a) the quoted cost of Materials represented on the bill of materials current at the time such Materials are acquired; or (b) the value of any Services performed on
work-in-progress at the time such Services are performed.
		
	“Taxes”	  	means federal, state and local excise, sales, use, VAT, duties, and transfer taxes and similar charges, including, without limitation, the medical device excise tax. “Taxes” do not include taxes based on the net income
of Flextronics or on real property owned by Flextronics.

  
 - 21 - 

 Portions of this Exhibit have been redacted because they are both (i) not material
and (ii) would be 
 competitively harmful if publicly disclosed. Information that was omitted has been noted in this document
with 
 a placeholder identified by the mark “[***]”. 

CONFIDENTIAL 
 AFFILIATE
ADOPTION AGREEMENT No. 2 
 This Affiliate Adoption Agreement (“Adoption Agreement” ) is made and entered into as
of January 17, 2020, with the effective date of November 2, 2019 (“Effective Date”), by and between 
  

	 	(1)	 Flextronics Medical Sales and Marketing, Ltd., a Mauritius company with limited liability, with business
address at [***] (“Flex Medical”) and 

  

	 	(2)	 Flextronics Manufacturing (Singapore) Pte Ltd, a Singapore company with limited liability, with registered
office at [***] (“Flex Kallang”) and 

  

	 	(3)	 Flextronics Shah Alam Sdn Bhd, with registered office at [***], (“Flex Senai”), and

  

	 	(4)	 Flextronics International GmbH, with registered office at [***] (“Flex 

Althofen”) (Flex Kallang, Flex Senai and Flex Althofen be referred to as “Flex Affiliate” or together
“Flex Affiliates”), and 
  

	 	(5)	 LumiraDx UK Limited with registered office at 3 More London Riverside, London, SE1 2AQ, England

 (“LumiraDx”). 

- each individually referred to as a “Party” and collectively the “Parties” - 

Whereas: 
  

	 	•	 	 Flex Medical concluded a Manufacturing Services Agreement with LumiraDx on October 18, 2017 (the
“MSA”) pursuant to which Flextronics Medical manufactures and delivers to LumiraDx certain products as set out in the MSA (“Products”). 

 

	 	•	 	 LumiraDx wish to order Services of Flex Kallang, Flex Althofen and Flex Senai under the MSA and wish to extend
the terms of the MSA to the Services provided by Flex Kallang, Flex Althofen and Flex Senai to LumiraDx. Therefore, the parties have entered into an Affiliate Adoption Agreement as of November 1, 2019 (“Affiliate Adoption Agreement
No. 1”). 

  

	 	•	 	 Due to clerical errors in the name and address of the Flex Affiliates, the parties terminated the Affiliate
Adoption Agreement No. 1 with the effective date of November 1, 2019. 

  

	 	•	 	 In consideration of the promises and other good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, the Parties hereby agree as follows: 

  

	1.	 DEFINED TERMS. 

Except as otherwise provided in this Adoption Agreement , capitalized terms used in this Adoption Agreement shall have the meanings given to
them in the MSA. Each term set forth below shall have the meaning given to it above or below when used in this Adoption Agreement with initial capital letters. 
  

	2.	 ADOPTION OF AGREEMENT. 

 

	 	2.1	 LumiraDx and Flex Medical agree that LumiraDX may order Products under the terms of the MSA from the following
Flex Affiliates: 

 i. Flex Kallang, 

ii. Flex Althofen, and 
 iii. Flex
Senai. 
  

	 	2.2	 Flex Kallang, Flex Althofen and Flex Senai each agree to be bound by the terms and conditions set forth in the
MSA when accepting purchase orders from LumiraDx. Flex Senai, Flex Kallang and Flex Althofen acknowledge that they have fully read and understand the terms and conditions set forth in the MSA. 

 CONFIDENTIAL 
  

	3.	 ENTIRE AGREEMENT. 

(a)    This Adoption Agreement No. 2, together with the MSA, constitutes the entire agreement among the Parties with
respect to the subject matter hereof and supersedes any previous oral or written agreements with respect to the subject matter hereof, including without limitation any nondisclosure agreements or memorandums of understanding or letters of intent
between the Parties with respect to the subject matter hereof. No modification of any provision of this Adoption Agreement shall be binding upon either Party unless executed in writing by that Party. 

 

	 	(b)	 In the event of any conflict between any provision of this Adoption Agreement and any provision of the MSA
(i) the provision of this Adoption Agreement shall prevail, and (ii) to the extent possible, such provisions shall be construed to minimize the conflict. 

 

	4.	 CONTROLLING LAW, DISPUTE RESOLUTION. WAIVER OF JURY TRIAL 

The Parties agree that this Adoption Agreement shall be subject to the same controlling law, dispute resolution and waiver of jury trial as the
MSA (as set out in Section 13.15 of the MSA). 
 [SIGNATURE PAGE FOLLOWS] 

  
 2 

									
	LumiraDx UK Limited	 		 	Flextronics Medical Sales and Marketing
			
	 /s/ David Scott
	 		 	 /s/ B. Vijayandran A/L S. Balasingam

	By:	 	David Scott	 		 	By:	 	B. Vijayandran A/L S. Balasingam
	Title:	 	Director	 		 	Title:	 	Director
				
		 		 		 	Flextronics International GmbH
				
		 		 		 	 /s/ Hannes
Moritz                    

		 		 		 	By:	 	Hannes Moritz
		 		 		 	Title:	 	Director
				
		 		 		 	 /s/ Erich Doerflinger

		 		 		 	By:	 	Erich Doerflinger
		 		 		 	Title:	 	Director
				
		 		 		 	Flextronics Manufacturing (Singapore) Pta
				
		 		 		 	 /s/ Jacob Philip Kanianthara

		 		 		 	By:	 	Jacob Philip Kanianthara
		 		 		 	Title:	 	Director
				
		 		 		 	Flextronics Shah Alam Sdn Bhd
				
		 		 		 	 /s/ Murugan Sinnakolandai

		 		 		 	By:	 	Murugan Sinnakolandai
		 		 		 	Title:	 	Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]